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ABSTRACT 
Aim:  The aim of this study was to describe the neuromuscular characteristics of Multiple 
Sclerosis (MS) patients.  To help explain the neuromuscular characteristics physical 
activity levels, body composition and blood lipid profile were measured.  In addition, 
Vitamin D was measured to determine if this was deficient in MS patients. 
Hypothesis:  We hypothesised that muscle fibre conduction velocity (MFCV) would be 
elevated and amplitude would be impaired in Multiple Sclerosis patients compared to an 
age and sex matched control group.  In addition, we hypothesised that physical activity 
levels would be reduced, body composition would exhibit a higher percentage fat, blood 
lipid profile would be less favourable and Vitamin D levels would be reduced in the 
group of MS patients. 
Methodology:  15 MS patients (53.8±10.5 years) and 14 age and sex matched control 
participants (54.6±9.6 years) were recruited for this study.  Patients with a disability 
status (EDSS) (92) of between 4 and 6 were included in this study.  All participants 
provided written informed consent after being fully informed of the procedures. 
An array of 4, 8mm Ag-AgCl electrodes was placed in a hard plastic mould in a straight 
line, leaving 12.5mm between each electrode.  The array was positioned on the vastus 
lateralis between the innervation zone and the distal tendon and was orientated to follow 
the muscle fibre pennation direction.  Electromyographic (EMG) data was collected via 
the electrodes whilst the participant carried out each contraction.  Muscle fibre 
conduction velocity (MFCV) and root mean square (RMS) were calculated from the raw 
EMG signal collected during each contraction. 
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The protocol was carried out on both legs.  Isometric knee extensions were standardised 
using the Bio-Dex Systems 3 Isokinetic Dynamometer and executed with the knee at 60° 
angle of flexion.  Participants were tested under four different contraction intensities; 20, 
40, 60 and 80% of the peak value of their maximum voluntary contraction (MVC).  Their 
MVC was established for both legs.  For each test condition the participant was required 
to carry out 3 isometric contractions for 7 seconds; each contraction was separated by 14 
seconds rest.  During each set of contractions the target force was visible on the Bio-Dex 
monitor.  Participants obtained visual feedback from the Bio-Dex throughout each 
contraction allowing the participant to adjust the force they were required to produce to 
maintain their target force. 
Whole body composition (fat mass, lean mass and bone mineral content) was measured 
by Dual-energy X-ray Absorptiometry (DEXA) using a Lunar Prodigy DF+ 13643, GE 
medical systems scanner.  Whole body and thigh composition were extrapolated from the 
digitalised results of the scan. 
Habitual physical activity was measured for 7 days using the GT1M Actigraph 
accelerometer, which was worn on the participants’ right hip during all waking hours.  
Data collected by and downloaded from the accelerometer was used to calculate each 
participant’s total and mean accelerometer counts per day. 
A fasted 10ml sample of venous blood was drawn from an antecubital vein using a 10ml 
syringe and a 15mm gauge needle.  The blood samples were analysed for total 
cholesterol, triglyceride and high density lipoproteins (HDL), low density lipoprotein 
(LDL) and Vitamin D concentration. 
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Results:  Initial findings revealed that the patient group exhibited a significantly faster 
(P<0.05) MFCV of the dominant leg than the control group.  The difference in MFCV of 
the non dominant leg was approaching significance (P=0.054).  However, after 
identifying a significant difference (P<0.05) in percentage fat of the thigh between the 
patient and the control group and revealing a strong positive correlation between MFCV 
and percentage fat of the thigh (r=0.697, P<0.001), percentage fat of the thigh was added 
into the analysis of variance for MFCV between the two groups.  Findings revealed that 
there was no significant difference (P>0.05) in MFCV over all the contractions between 
the groups.  There was no significant difference (P>0.05) in MFCV between the 
dominant and non-dominant leg within each group. 
Analysis of the RMS data revealed that there was no significant difference (P>0.05) over 
all the contractions between the patient and the control group in either the dominant or 
the non-dominant leg.  However there was a highly significant difference (P<0.001) in 
RMS between contraction intensity in both legs in both groups. 
There was a significant difference (P<0.05) in maximum voluntary contraction (MVC) 
between the patient (133.65±54.20nm, 115.21±43.41nm) and the control group 
(175±43.94nm, 160.14±47.55nm).  However, torque production per gram of muscle mass 
was not significantly different between the patient (0.024±0.0048nm.g-1, 
0.021±0.0045nm.g-1) and the control (0.026±0.0076 nm.g-1, 0.024±0.0047 nm.g-1) group.  
No significant difference (P>0.05) was identified between the dominant and non-
dominant leg within each group. 
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There was no significant difference (P>0.05) in absolute lean thigh mass (LTM) between 
the two groups however the difference in relative lean thigh mass (lean thigh mass/lean 
body mass*100) between the groups was approaching significance (P=0.077). 
The patient group exhibited a significantly (P<0.05) higher whole body (43.8±7.2%, 
34.28±9.64%) and thigh fat (44.46±7.54%, 34.25±10.34%) percentage than the control 
group.  There was no difference (P>0.05) in whole body or thigh bone mineral density 
(BMD) between the groups. 
The patient group was significantly (P<0.05) less physically active than the control 
group; this was evident from their total accelerometer counts/day (patients 
167088±113586, control 316401±108982) and mean accelerometer counts/day (patients 
206.4±139.5, controls 364.5±120.6). 
There was no significant difference (P>0.05) in blood lipid profile (cholesterol, 
triglycerides, HDL or LDL) between patients and control group.  However there was a 
significant difference (P<0.05) in serum Vitamin D concentration between the patient and 
the control group. 
Conclusion:  MS patients exhibited faster MFCV with a similar number of motor units 
recruited than healthy ages and sex matched controls.  However, an increased quantity of 
subcutaneous fat artificially elevates MFCV (110) and MS patients in this study exhibit 
higher percentage fat than the controls.  Therefore, when accounting for this confounding 
variable we then showed that there was in fact no difference in MFCV between the 
groups.  However the patients MFCV responded differently to the increased contraction 
intensity than the controls which suggests altered neuromuscular processing within the 
patient group. 
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The MS group had reduced physical activity levels which caused a slight disuse atrophy 
of the lower limbs which did not compromise muscle quality.  Therefore, similar quality 
of the muscle has resulted in unaltered neuromuscular recruitment in MS patients. 
Overall, the results indicate that there was no difference in neuromuscular characteristics 
of MS patients compared to age and sex matched controls, even in the presence of altered 
body composition and physical activity levels. 
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Multiple Sclerosis (MS) is a degenerative, demyelinating disease of the central nervous 
system (CNS) (154) characterised by spinal chord lesions which cause subsequent 
neuronal damage, resulting in marked physical disability (33).  As a consequence of the 
neuronal damage of the CNS the delivery of neural activity to skeletal muscle is affected 
(148; 150).  Therefore it is well accepted that the neural activity received by the muscle 
dictates the phenotypic expression of the muscle (133).  Buller at el (1960) (21) 
demonstrated that when nerves from fast motor units are made to innervate a slow 
muscle, the muscle is transformed into a fast muscle and likewise slow motor units 
converted fast muscle to slow.  In addition, Roy et al (1992) (143) demonstrated that after 
6 months of spinal chord isolation mammalian skeletal muscle exhibited a significantly 
greater proportion of type II fibres.  Concurrently, Castro et al (1999) (29) demonstrated a 
significant shift towards type IIx fibres in human patients within 6 months of complete 
spinal chord injury. 
MS is characterised by spinal chord lesions which affect the neural transmission along the 
axon (154), therefore the neural activity received by the muscle of MS patients will be 
altered.  Lack of neural innervation can also result from skeletal muscle inactivity as a 
result of bed rest, denervation, hind limb unloading, immobilisation or micro gravity 
(181). 
Inactivity results in muscle atrophy which is characterised by a decrease in protein 
content, fibre diameter, force production, fatigue resistance (78) and a higher proportion 
of type II muscle fibres (101).  As it has been demonstrated that a higher proportion of 
type II fibres can be indicative of disuse, it is reasonable to expect MS patients to exhibit 
a higher proportion of type II muscle fibres compared to equivalent controls.  Kent-Braun 
et al (1998) (82) demonstrated that MS patients exhibited fewer type I muscle fibres in 
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the tibialis anterior than control participants. Kent-Braun et al (1994) (83) also revealed 
that phosphocreatine (PCr) resynthesis was slower in MS patients compared to controls; 
which indicates that MS patients exhibited a reduced oxidative capacity to generate ATP 
which is indicative of an increased expression of fatigable fast twitch muscle fibres.  In 
addition, a strong positive correlation (r=0.84) between relative area of fast twitch fibres 
and muscle fibre conduction velocity (MFCV) measured using surface EMG was 
revealed by Sadoyama et al (1988) (145).  Therefore the rate of the MFCV measured 
using surface EMG technique is indicative of the proportion of fast twitch fibres within 
the muscle. 
It has been shown that elevated expression of type II fibres within the muscle is indicative 
of disuse (82).  Differences in fibre type expression between MS patients and controls 
have been elucidated using histochemical techniques (82).  However to our knowledge 
differences in MFCV between MS patients and controls using surface EMG technique 
have not been investigated. 
Therefore the present study employed surface EMG technique to investigate if there was 
a difference in MFCV between MS patients and control participants.  In order to explain 
any differences in MFCV physical activity and body composition was also measured. 
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2.1. Defining Multiple Sclerosis 
Multiple Sclerosis (MS) is a degenerative, demyelinating disease of the central nervous 
system (CNS) (154) characterised by spinal chord lesions which cause subsequent 
neuronal damage, resulting in marked physical disability (33).  Patients with MS 
experience numerous symptoms, including spasticity, fatigue, cognitive dysfunction, 
depression, bladder dysfunction, bowel dysfunction, sexual dysfunction and pain (33).  
The disease is characterised by episodes of relapse and remission however, the disease is 
inevitably progressive (154).  About 85% of patients present with the relapsing-remitting 
form of MS, where symptoms suddenly deteriorate then remain static for a period of 
time.  The remaining 15% present without relapses but show a slow progressive pattern 
where the symptoms steadily worsen over time.  This is known as primary progressive 
MS (116). 
Jean-Martin Charcot identified MS as a distinct entity in 1868 (161).  Since then, research 
into the cause, nature, treatment and cure of MS has been ongoing.  Today, understanding 
of the disease has improved greatly, however, the cause of the disease remains a mystery 
and there is still no known cure.  This literature review aims to outline current opinion on 
the epidemiology and aetiology of MS, explore the affect the disease has on the 
neuromuscular system and investigate the benefits of physical activity for MS patients.  
The review also looks at the use of surface EMG techniques to determine muscle fibre 
conduction velocity. 
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2.2. Epidemiology of Multiple Sclerosis 
2.2.1. Prevalence of MS 
There is considerable variation in the prevalence of MS throughout the world however 
Scotland has the highest prevalence of Multiple Sclerosis (142) with an annual incidence 
of 12.2 per 100,000 in the South East of Scotland (142) which is almost double that 
reported for the whole of the UK (2).  In addition, an annual incidence of MS of 7.2 per 
100,000 was reported in Tayside (44); 5.7 per 100,000 in Glasgow (118) and 144 per 
100,000 in Grampian (149).  Clustering of MS cases has also been reported in Orkney 
and Shetland Islands as well as the Outer Hebrides (38).  The prevalence rate of probable 
MS has been reported to be as high as 152 per 100,000 in the Shetland Islands (38); 258 
per 100,000 in the Orkney Islands (137) and 82.1 per 100,000 for the Outer Hebrides 
(38).  A number of suggestions have been made to explain why the prevalence of MS is 
elevated within island communities.  A Dutch study by Hoppenbrouwers et al (2007) (73) 
suggests familial aggregation of MS in a genetically isolated population.  As the gene 
pool within the island is largely closed, the genes which are susceptible to MS are more 
likely to be passed on to the next generation.  Moreover, environmental factors (which 
will be discussed in the following sections) have been suggested to trigger the 
development of MS (7; 8) therefore the isolated environment of the islands may hold the 
key to what the environmental trigger is.  Taylor et al (1980) (162) suggests that the 
effect of migration and social structure within the isolated communities may elevate the 
epidemiological findings.  Taylor et al (1980) (162) suggests that lower emigration and 
higher immigration rates, of people with MS, to the island in addition to higher general 
rate of emigration from the islands may account in part to the high prevalence rates 
documented in the island communities in Scotland.  In addition, Taylor et al (1980) (162) 
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postulated that lower rates of immigration to the islands may have influenced the elevated 
rates of MS recorded in the islands. 
Furthermore, the disease presents with a bias towards woman, with the prevalence 
amongst women almost double that of men (44).  A study by Orton et al (2006) (127) 
revealed a sex bias of MS towards females in Canada with a ratio of 3.2:1.  In addition, 
Iversen (1982) (77) revealed that there were 296 male and 445 female deaths in Scotland 
attributed to MS between 1973 and 1980, which also highlights the sex bias that MS 
exhibits. 
There is a consensus in many countries that the incidence and prevalence of MS is 
increasing (127; 180) however this may be attributed to an increase in diagnosis due to an 
increased number of neurologists (161) and more clearly defined diagnostic criteria (108; 
136). 
2.2.2. Effect of Latitude 
The prevalence has been reported to increase as distance from the equator increases (25).  
One theory suggests that populations closer to the equator are exposed to more sunlight 
and therefore exhibit a higher level of serum Vitamin D, which is considered to have a 
protective effect to developing MS (7).  This theory may not be substantiated as it has 
been shown that Vitamin D insufficiency is also high among populations with highly 
pigmented skin which make ultraviolet light less efficacious (71). 
The prevalence of MS is greater in Caucasian populations than Asian or African 
populations (7).  This may be attributed to the theory that MS is considered to be more 
prevalent the further you move away from the equator (25) as Caucasians generally exist 
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further away from the equator than African or Asians.  It could however be due to a 
genetic predisposition within the Caucasian population towards developing MS (142). 
Overall the prevalence of MS is increasing and prevalence in Scotland remains 
particularly high (44; 118; 142).  Research into the cause, nature, treatment and cure of 
MS continues to be a high priority within Scotland due to the disproportionately high 
prevalence within Scotland (38; 44; 91; 142; 162; 180). 
2.3. Aetiology of Multiple Sclerosis 
MS is a complex disease and occurs because of a complex interaction between genetic 
and environmental factors (99). 
2.3.1. Immigration Studies 
Immigration studies have provided valuable information of the genetic risk of different 
ethnic groups to developing MS (36-42; 49; 50).  The incidence of MS in migrants tends 
to be intermediate between that of their birth place and that of their residence, and close 
to the latter when migration occurs in childhood (58).  However the shift in risk is not 
consistent between immigrants who move from low risk to high risk areas and those who 
move from high risk to low risk (58).  High risk areas are considered to be geographical 
locations where the prevalence and incidence of MS is high, such as Scotland (44; 118; 
142). 
Dean and Elian (1993) (37) revealed that mortality rates from MS over a 22 year period 
of UK immigrants to South Africa were twice that of the white South African born 
population, but only a third of that of the population of England and Wales.  Therefore 
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UK residents who immigrate to low risk areas lower their risk from what it was in the UK 
but not to the level of the indigenous population. 
On the other hand, Dean et al (1976) (40) reported that few immigrants in Greater 
London from new commonwealth countries within Asia, Africa, America (including 
West Indies) and Europe (Gibraltar, Malta and Gozo) were discharged from hospital with 
the diagnosis of MS compared to people born in the UK.  In addition Dean et al (1977) 
(36) concluded that MS is rare in immigrants resident in England and Wales who were 
born of Indian, Pakistani or African origin.  Immigrants from new commonwealth 
countries exhibit one eighth of the risk of developing MS as UK born residents (58).  
Therefore immigrants to the UK from new commonwealth countries retain their low risk 
status although they reside in a high risk area. 
Further studies examined whether the low risk of MS observed among immigrants to the 
UK from the West Indies, the Indian subcontinent, and Africa was shared by the UK born 
children of these immigrants.  Elian and Dean (1987) (49) reported that the UK born 
children of West Indian immigrants had similar incidence and prevalence of probable MS 
to that of the indigenous population of Northern Ireland and the Irish Republic.  In 
addition, Elian et al (1990) (50) concluded that children born in the UK of Asian, African 
and West Indian immigrants have a similar prevalence of MS as the UK population. 
Although MS is a complex disease and occurs because of an interaction between genetic 
and environmental factors (99) these studies indicate that the prevalence and incidence of 
MS is equivalent across ethnic groups who are born and live in the UK.  These findings 
provide strong evidence that the cause of the disease is primarily environmental and 
therefore it is potentially preventable (49). 
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Further evidence for this, Dean and Kurtzke (1971) (39) reported that white immigrants 
who arrived in South Africa before the age of 15 acquired the lower risk of their country 
of destination.  In contrast white immigrants arriving after they were 15 years of age 
appeared to retain the higher risk of their country of origin.  Therefore the age at 
immigration from an area of high risk to an area of low risk affected the likelihood of 
developing the disease.  This suggests that children are more susceptible to the 
environmental factor which triggers MS.  This has led to much research being carried out 
into the environmental conditions exposed to MS patients during their childhood (3; 76; 
135; 170). 
2.3.2. Environmental Factors 
Several environmental factors have been suggested to play a role in the development of 
MS.  However the two which have the most compelling evidence are: sunlight (62; 67; 
76; 170; 171), and the epstein-barr virus (EBV) (3; 7; 9; 66; 67; 135).  These factors can 
be categorised into infectious and non infectious factors (7; 8). 
2.3.3. Sunlight 
The inverse association between solar radiation and prevalence of MS was first observed 
in 1960 (1).  More recently Sloka et al (2008) (152) demonstrated a significant negative 
correlation between MS incidence and level of sunlight.  This indicates that MS incidence 
decreased with increased exposure to sunlight.  These findings are consistent with the 
theory that MS prevalence increases with increasing distance from the equator (36-42; 
49; 50) (as previously discussed).  In addition, Islam et al (2007) (76) reported that sun 
avoidance seems to precede the diagnosis of MS when studying monozygotic twins.  
Goldacre et al (2008) (62) also reported that skin cancer was significantly less common in 
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people with MS, which indicated that MS patients have been exposed to less sunlight.  
Concurrently, van der Mei et al (2003) (170) concluded that sun exposure during 
childhood and early adolescence is associated with reduced risk of MS.  Therefore 
insufficient ultraviolet light may influence the development of MS. 
Sunlight plays an important role in Vitamin D metabolism (97).  Vitamin D3 is 
synthesised in the skin with exposure to sunlight and is then metabolised by the liver and 
the kidneys to produce the active form of Vitamin D (97).  Munger et al (2006) (117) 
reported that high circulating levels of Vitamin D is associated with lower risk of MS.  
Vitamin D has a primary role in maintaining calcium homeostasis (45), however Vitamin 
D is also utilised as an immunomodulator (23; 96). 
2.3.4. Epstein-Barr Virus 
The epstein-barr virus (EBV) is a herpes virus and infects more than 90% of the 
population (141; 141).  Infection with EBV is usually asymptomatic in childhood but can 
cause infectious mononucleosis in adolescents and adults (9).  However only a small 
proportion of those infected with EBV develop MS (72).  Haahr et al (2004) (66) 
documented an association between late EBV infection and an increased risk of 
developing MS.  These findings have led to the theory known as the “Hygiene 
Hypothesis” according to which protection against MS is conferred by persistent effect 
on the immune system by repeated infection in childhood (6).  A further study by 
Ponsonby et al (2004) (135) reported that high infant sibling exposure in the first 6 years 
of life was associated with a reduced risk of MS, possibly by altering childhood infection 
patterns and related immune response.  Therefore if children are brought up too clinically 
they will be less likely to be exposed to infection at the critical stage of development.  
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Exposure to infection at this stage seems to have a protective effect against developing 
MS (135).  Consequently, the association between the EBV and risk of MS is well 
documented; however the exact mechanism by which the EBV wields this effect remains 
to be elucidated. 
In addition, a positive association has been found between higher education and MS risk 
(7); this finding is consistent with the hygiene hypothesis and with late infection of EBV.  
This suggests that children brought up with more affluent parents are less likely to 
experience repeated infections.  This is also consistent with low rates of MS in 
developing countries (6), where living conditions are less sanitary and fresh water is not 
available hence children are more likely to experience infection at an early age. 
2.3.5. Immune Response in MS 
Current research suggests that proinflammatory cells and mediators may be triggered by 
environmental factors (as previously discussed) to mediate the disease in a genetically 
susceptible host (12).  An agent triggers an immune response; autoreactive T cells in the 
periphery are attracted to the blood brain barrier (BBB).  Activated T cells adhere to the 
endothelium of the BBB and release an enzyme (matrix metalloproteinase) which 
facilitates infiltration of activated T cells across the BBB into the CNS (12).  Activated T 
cells within the CNS cause myelin damage and axonal injury; reactivation of these cells 
within the CNS mediates further damage (150). 
Although several environmental factors have been suggested as triggers for the 
development of MS, no single factor has been identified as the causal factor.  This could 
mean that the effect of each factor is small or that the factors exert an additive effect upon 
one another.  Holmoy (2008) (72) suggests that Vitamin D protects against MS by 
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modulating the immune response to EBV and that low vitamin D status facilitates 
detrimental activation of the autoreactive T cells and skews the immune response to EBV 
in the proinflammatory direction.  This suggests that more than one environmental factor 
must be present in order to develop MS.  Therefore if the environmental risk factors are 
identified, there is the possibility of primary prevention of the disease (7; 72). 
2.3.6. Treatment of Multiple Sclerosis 
The treatment of MS has three components; disease modification, relapse treatment and 
symptom management (33). Immunomodulators or immunosuppressants such as beta 
interferon and mitoxantrone (56) are disease modifying agents. These drugs have been 
shown to reduce the number and frequency of relapses in patients with relapsing-
remitting MS.  The exact mechanism of how these drugs work is not certain, however it 
is known that they reduce the infiltration of the activated T cells across the BBB, thereby 
reducing the extent to which the T cells can cause damage within the CNS.  Although 
these drugs are effective in reducing the number of relapses, they also produce side 
effects.  Mitoxantrone can cause cardiotoxicity (56) therefore the function of the heart 
must be monitored when the drug is being administered and if any adverse adaptations 
occur the treatment would have to stop. 
Corticosteriods are also used to treat acute exacerbation of MS.  These are among the 
most potent anti-inflammatory and immunosuppressive drugs available and they work by 
restoring the BBB and induce T cell apoptosis (56), therefore reducing damage within the 
CNS. 
Symptom management can vary extensively between patients as the symptoms reflect the 
neural pathways that have been damaged.  Thus the clinical management of MS patients 
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is complex, requiring careful attention to multiple disease symptoms as well as symptoms 
arising from therapeutic interventions (68). 
2.4. The Neuromuscular System 
2.4.1. The Central Nervous System 
The central nervous system (CNS) is a communication network which is composed of 
two different types of cells; neurons which form the communication pathway and glia 
cells which support the function of the neurons.   Different glia cells have been identified 
within the CNS; astrocytes, oligodendrocytes and microglia (15).  The oligodendrocyte is 
a myelin forming cell (15) and the myelin sheath is formed by the spiral wrapping of  
oligodendrocytes plasma membrane extensions around the axons of the CNS (151). 
The oligodendrocyte produces myelin which is composed of cholesterol, phosphlipids 
and glycolipids (15).  This multilayered, myelin containing membrane insulates the 
axonal cytoplasm from the extracellular fluid (154) resulting in a faster transmission of 
the nerve impulse along the axon (154; 172).  This method of nerve transduction, where 
the signal appears to jump from sheath to sheath is called saltatory conduction (15).  Each 
myelin sheath is separated by a section of exposed axolemma, these are known as the 
nodes of ranvier (15; 151; 154; 172).  The axolemma at the nodes of ranvier contain a 
high density of sodium channels to ensure a rapid transmission of the action potential 
along the neuron (15). 
In MS the oligodendrocytes are damaged (15; 15; 43; 150) resulting in the exposure of 
the axolemma to the extracellular fluid.  This reduces the speed of neural transmission at 
the point of the lesion (15; 154).  The slowing down of the impulse at the lesion can have 
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a profound impact on the overall rate of signal transmission.  When the signal is impaired 
or fails the effect is evident in co-ordinated movement in the MS patient, most notably in 
the patient’s gait (125). 
Blakemore and Patterson (20) demonstrated in 1978 that remyelination of demyelinated 
axon is made possible by remyelination competent cells generated by mitosis.  In addition 
Carroll and Jennings (1994) have shown that remyelinating cells are generated soon after 
demyelination.  Remyelination occurs in many MS lesions but becomes increasingly 
incomplete or inadequate and eventually fails in the majority of lesions (15) as a 
consequence patients experience an increase in MS symptoms; such as spasticity and 
ataxia (125).  Efforts to understand the causes for this failure of regeneration have fuelled 
research into the biology of remyelination and the complex interdependent cellular and 
molecular factors that regulate this process (30). 
In addition to demyelination, axonal degeneration plays an important role in the 
accumulation of physical disability in MS patients (53; 54; 150).  Although MS is 
regarded primarily as a demyelinating disease, axonal loss is likely to contribute to much 
of the resulting disability (150).  Irvine et al (2008) (75) demonstrated that prompt 
remyelination protects axons from demyelination-associated axon loss and that 
remyelination failure contributes to the axonal loss that occurs in multiple sclerosis.  In 
MS remyelination occurs but it is incomplete and poorly maintained (138; 139) hence the 
axolemma is therefore exposed which results in increased disability experienced by the 
MS patient. 
As previously discussed, the CNS is restricted in its capacity to support the re-extension 
and rearrangements of axonal connections (22), therefore maintaining function capacity 
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after axonal degradation is limited.  The nature, location, extent and maturity of the 
neurological insult influences the degree and specificity of axonal growth necessary to 
improve function (22).  Bareyre et al (2004) (13) demonstrated in adult rats that local 
growth of damaged corticospinal tract axon resulted in new synapse formation.  
However, axon re-growth remains limited within the mature CNS (22) therefore neuronal 
repair does not elicit functional capacity in multiple sclerosis patients (18; 22).  
Spillmann et al (1998) (158) identified that membrane proteins from CNS myelin were 
inhibitory to neurite outgrowth.  Therefore a complex system of destruction and repair 
exists within the central nervous system.  The exact mechanism remains to be elucidated. 
Wujek et al (2002) (179) demonstrated with animal models of MS, a causal relationship 
between inflammation, axon loss, and irreversible neurological disability.  Papadopolos et 
al (2006) (129) also concluded that axonal loss is the main determinant of irreversible 
neurological disability in rats.  In addition the “axonal hypothesis” states that cumulative 
axonal loss causes irreversible disability during progressive multiple sclerosis (18). 
Therefore, demyelination and axonal degradation together result in irreversible 
destruction of the CNS in multiple sclerosis (18; 27; 30; 129; 179). 
2.4.2. Skeletal Muscle 
As a consequence of the neuronal damage of the CNS, the delivery of neural activity to 
skeletal muscle is affected (148).  Buller at el (1960) (21) demonstrated that when nerves 
from fast motor units are made to innervate a slow muscle, the muscle is transformed into 
a fast muscle and likewise slow motor units converted fast muscle to slow.  In addition, 
Roy et al (1992) (143) demonstrated that after 6 months of spinal chord isolation (which 
has a similar effect to disuse of skeletal muscle) mammalian skeletal muscle exhibited a 
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significantly greater proportion of type II fibres.  Concurrently, Castro et al (1999) (29) 
demonstrated a significant shift towards type IIx fibres in human patients within 6 months 
of complete spinal cord injury.  Therefore it is well accepted that the neural activity 
received by the muscle dictates the phenotypic expression of the muscle (133). 
MS is characterised by spinal chord lesions which effect the neural transmission along the 
axon (154), therefore the neural activity received by the muscle of MS patients will be 
altered.  Reduced neural innervation can also result from skeletal muscle inactivity as a 
result of bed rest, denervation, hind limb unloading, immobilisation or micro gravity 
(181).  The effect of reduced innervation to the muscle due to MS is similar to the effect 
of skeletal muscle inactivity. 
Inactivity results in muscle atrophy which is characterised by a decrease in protein 
content, fibre diameter, force production fatigue resistance (78) and a higher proportion 
of type II muscle fibres (101).  As it has been demonstrated that a higher proportion of 
type II fibres can be indicative of disuse it is reasonable to expect MS patients to exhibit a 
higher proportion of type II muscle fibres compared to equivalent controls.  Kent-Braun 
et al (1998) (82) demonstrated that MS patients exhibit fewer type I muscle fibres in the 
tibialis anterior than control participants.  In addition a strong positive correlation 
(r=0.84) between relative area of fast twitch fibre and muscle fibre conduction velocity 
(MFCV) measured using surface EMG was revealed by Sadoyama et al (1988) (145).  In 
addition, Garner and Widrick (2002) (60) demonstrated that MS patients exhibited a 
subtle fast MCH isoform co expression which suggested a trend towards an increased 
expression of type II fibres with the skeletal muscle.  Kent-Braun et al (1994) revealed 
slower phosphcreatine resynthesis (PCr) following exercise in MS patients, which is 
suggestive of impaired oxidative capacity within the skeletal muscle.  These findings too 
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are indicative that MS patients exhibit a higher proportion of type II fibres within the 
muscle. 
It is clear from the literature that there are alterations within skeletal muscle of MS 
patients (26; 74; 82), however it is difficult to quantify the cause of these changes as 
reduced innervation can arise for a number of reasons, such as inactivity, MS or bed rest.  
The problem is also confounded by the fact that MS patients are less active (122) than 
controls and hence their muscle would exhibit an effect of disuse before taking into 
account the effect of the disease.  Therefore it is difficult to quantify how much of the 
alteration in skeletal muscle in MS patients is down to disuse or how much is down to the 
disease.  This point remains to be elucidated. 
2.4.3. Effect of Temperature on the neuromuscular system in MS 
The effect of temperature on nerve transduction in pathological conditions is well 
documented (11; 31; 132; 154; 175).  White et al (2000) (175) demonstrated improved 
walking performance and improvement in fatigue scores in MS patients after 30 minutes 
of lower body immersion in 16-17°C water.  In addition, Capello et al (1995) (24) 
concluded that 45 minutes of cooling with a cooling device led to improvements in 
strength and fatigue for up to 2 hours in MS patients. 
Heat worsens and cooling improves the negative symptoms of multiple sclerosis.  Sitting 
in a cold bath can turn the “disease off” and gives an individual back the freedom to work 
or exercise (11).  Temperature effects the disease by affecting the ability for the neural 
signal to be transmitted past the point of a lesion within the CNS (154).  The increase in 
nodal widening (173) results in increased electrical capacitance of the node therefore the 
current required to depolarise the node to its firing threshold is increased (154).  The 
Literature Review 
 19
current received at the node is greater than the current required to depolarise the node in 
order to ensure that depolarisation occurs.  The difference between the two currents is 
called the safety factor.  In MS the safety factor is reduced due to widening of the nodal 
gap thereby allowing the current to be dissipated away from the node (154).  If the 
current required by the node increases the safety factor is reduced.  The more damaged 
the node becomes the more current is required to depolarise the node and continue the 
signal along the axon.  Therefore the more damaged the node the smaller the safety factor 
and the smaller the safety factor the less likely the signal is to be propagated. 
Temperature can vastly influence the safety factor and it is because of this that cooling 
therapy has a beneficial effect on the symptoms of MS. 
2.5. Habitual Physical Activity of MS Patients 
Previous research supports the contention that MS patients are less active than control 
participants (60; 82; 122).  Due to the debilitating nature of the disease it is not surprising 
that MS patients are habitually less active than healthy individuals. 
2.5.1. Benefits of Physical Activity for MS patients 
For many years MS patients were advised to avoid exercise because of excessive fatigue 
and thermosensitivity (131).  Heat worsens and cooling improves negative symptoms of 
MS (11) therefore as patients exercise and body temperature increases symptoms worsen 
and they become more disabled.  Exercise prescription must therefore be very specific for 
MS patients to ensure that they are given exercise that is going to benefit them whilst 
ensuring their safety and comfort.  Numerous studies (17; 65; 119; 159; 163; 176; 178) 
have investigated the benefits of different modes and intensities of exercise programmes 
for MS patients.  Bjarndottir et al (2007) (17) investigated the effect of a five week 
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exercise programme on patients with mild MS.  After a 5 week programme of combined 
aerobic and resistance exercise, an increase of 14.7% in VO2peak, 18.2% in peak 
workload and 27.3% in anaerobic threshold was observed in the exercise group.  All 
these parameters were significantly different from the control group.  The study also 
showed a tendency towards an improved quality of life in the exercise groups.  This study 
concluded that a 5 week exercise programme of combined aerobic and resistance training 
was adequate to improve physical fitness in patients with mild MS. 
Documented benefits of physical activity for MS patients include decreased oxygen 
consumption (119), reduced motor fatigue (159) improved gait kinematics (65) increased 
stepping performance (178), improved physical fitness (17) as well as having a positive 
effect on the psychological well being of the patient (107; 115). 
Evidence is also emerging which suggests that physical activity may influence the 
mechanism of the disease.  Gold et al (2003) (61) investigated the response of serum 
nerve growth factor (NGF) and brain derived neurotrophic (BDNF) factor concentrations 
to standardized acute exercise in MS patients and controls.  They revealed that 30 
minutes of moderate exercise induced significant BNDF production in both MS patients 
and controls.   BNDF is thought to play a role in preventing neural cell death and 
favouring the recovery process, neural regeneration and remyelination (47).  As a 
consequence of the previous study White and Castellano (2008) (174) suggested that 
since axonal loss and cerebral atrophy occur early in MS, exercise prescription in the 
acute stage could promote neuroprotection, neuroregeneration and neuroplasticity and 
reduce long-term disability.  This remains a relatively new concept and further research is 
required on the volume of exercise required to induce the response and elucidate if the 
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benefits are long lasting in MS patients.  However this theory does present a novel 
approach for exercise to be utilised as a disease modifying therapy in MS. 
2.6. Surface Electromyography 
The surface electromyography (sEMG) technique is a non invasive technique used to 
detect myoelectical signals within the muscle (5).  The sEMG technique involves at least 
two EMG signals, with surface electrodes aligned parallel to the muscle fibre and 
between the innervation zone and the tendon.  Using surface electrodes, the recorded 
EMG signal is a summation of activities from numerous motor units containing a large 
number of fibres. 
The application of sEMG has mainly been utilised to investigate the neuromuscular 
characteristics and adaptations in the field of sport and exercise science and in 
pathological conditions (52).  The present study employed sEMG technique to investigate 
alterations in neuromuscular characteristics in a clinical population.  Sadoyama et al 
(1988) (145) demonstrated a  strong positive correlation (r=0.84) between relative area of 
fast twitch fibre and muscle fibre conduction velocity (MFCV) measured using surface 
EMG.  Therefore the technique can be used to demonstrate non-invasively the proportion 
of type II fibre expressed within the muscle. 
Nielson et al (2007) (124) documented that innervation zone distribution substantially 
influenced amplitude and characteristic spectral frequencies.  However, Roy et al (1986) 
(144) previously reported that estimates of conduction velocity were most stable between 
the distal tendon and adjacent distal tendon.  In addition, the level of subcutaneous fat 
between the sacrolemma and the electrode has been documented as having an affect on 
estimated MFCV (110).  Neilson et al (2007) (124) also demonstrated that MFCV was 
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elevated under conditions with elevated subcutaneous fat, which is as a consequence of a 
special filtering effect.  Therefore higher levels of subcutaneous fat appear to artificially 
elevate the MFCV estimate. 
Masuda and Sadoyama (1987) (103) investigated which skeletal muscles were most 
appropriate for the use of sEMG and concluded that mostly the biceps brachii, vastus 
lateralis and the tibialis anterior were used.  The present study utilised the vastus lateralis 
for sEMG data collection. 
2.7. Present Study 
Aim:  The aim of this study was to describe the neuromuscular characteristics of Multiple 
Sclerosis (MS) patients.  To help explain the neuromuscular characteristics physical 
activity levels, body composition and blood lipid profile were measured.  In addition, 
Vitamin D was measured to determine if this was deficient in MS patients. 
Hypothesis:  We hypothesised that muscle fibre conduction velocity (MFCV) would be 
elevated and amplitude would be impaired in Multiple Sclerosis patients compared to an 
age and sex matched control group.  In addition, we hypothesised that physical activity 
levels would be reduced, body composition would exhibit a higher percentage fat, blood 
lipid profile would be less favourable and Vitamin D levels would be reduced in the 
group of MS patients. 
 
  
3. Methodology 
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3.1. Participants 
In this study a group of MS patients were compared to a group of healthy age and sex 
matched control participants. 
3.1.1. Characteristics of Participants 
Originally 17 patients were recruited to participate in the study however one patient 
withdrew and another was excluded from the study.  The MS group consisted of 15 
patients, 8 women and 7 men, aged 53.72 years ± 10.5 year (mean ±SD; range 36-69) and 
all 15 were included for data analysis.  The patients were recruited through local MS 
societies.  To be included, patients had to suffer from MS, be aged between 18 and 70 
years and have impaired mobility.  All patients were considered to fall between 4 and 6 
on Kurtzke expanded disability status scale (EDSS)(92).  A rating of 4 describes a patient 
fully ambulatory without aid, self-sufficient, up and about some 12 hours a day despite 
relatively severe disability whereas a rating of 6 describes a patient who needs 
Intermittent or unilateral constant assistance (cane, crutch, brace) to walk. 
18 control participants were recruited and tested however 4 participants were rejected 
from the study due to incorrect electrode placement.  Therefore 14 participants; 6 women 
and 8 men, aged 54.59 years ± 9.6 years (mean ±SD; range 37-70) were included for data 
analysis.  These participants were recruited through local MS societies, posters 
throughout the university and local public buildings and the university web site.  To be 
included in the study, participants had to be within the age range of the MS group and 
have an equivalent BMI. 
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Table 3-1 Descriptive Characteristic of Participants 
 Patients Control P Value 
Participants (n) 15 14 0.707 
Age (yr) 53.72±10.5 54.59±9.6 0.752 
Weight (Kg) 77.97±22.02 77.85±15.54 0.987 
Height (M) 1.66±0.09 1.71±0.09 0.227 
BMI 27.73±6.11 26.51±4.01 0.080 
The laboratory procedures were carried out at the University of Stirling physiology 
laboratory within the Gannochy Sports Centre.  Participants reported to the lab for 
8:30am having fasted for 12 hours overnight prior to their visit.  Participants read the 
participant information sheet and had the opportunity to ask questions before being asked 
to complete two consent forms and complete a pre-exercise risk evaluation questionnaire. 
3.1.2. Exclusion Criteria 
Participants were excluded from the trial if their pre-participation questionnaire revealed 
any major contraindications to exercise; such as high blood pressure, recent cardiac 
problems.  No-one was excluded from the trial on these bases.  Women who were 
pregnant or potentially pregnant or those who were breast feeding were excluded from 
the trial.  One patient was excluded from the trail on the basis that she became pregnant. 
3.1.3. Consent 
All participants were fully informed of the procedures and risks involved in the study 
before providing written informed consent.  Participants were free to withdraw from the 
study at any point and without giving a reason. 
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3.1.4. Ethical Approval 
This study was performed according to the Declaration of Helsinki and was approved by 
the University of Stirling, Department of Sport Studies Ethics Committee (Reference: 
#161- See Appendix A) 
3.2. Laboratory Procedures 
3.2.1. Blood Sample 
A 10ml sample of venous blood was drawn from the antecubital vein using a 10ml 
syringe and a 15mm gauge needle.  The blood was decanted into one 5ml container and 
left to clot for one hour.  The remaining 5ml of blood was separated into two 2.5ml 
containers containing EDTA.  The EDTA is as an anticoagulant which stops the blood 
sample from clotting.  Both samples were centrifuged at 5000g for 10 minutes.  The clear 
serum was then separated from the sample using a pipette and emptied into the 
appropriate vial (yellow for lipid analysis and white for vitamin D analysis) and stored in 
a secured freezer at -80oC. 
All samples were transported, in dry ice, to Glasgow Royal Infirmary where the samples 
were analysed by the NHS Greater Glasgow and Clyde Clinical Biochemistry Service 
(34). 
The blood samples were analysed for total cholesterol, triglyceride and high density 
lipoproteins (HDL) using enzymatic techniques.  Low density lipoprotein (LDL) 
concentration was calculated using the equation: cholesterol – HDL – (Trig*0.46).  
Fasted blood samples were used for this analysis as it has been shown that lipoprotein 
cholesterol concentration measured in the fed state differs significantly to those measured 
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in the fasted state (32).  Vitamin D content was determined using Tandem Mass 
Spectrometry as described by Maunsell et al (106). 
3.2.2. Initial Measurements 
Height was measured with bare feet with the participant standing with their feet shoulder 
width apart.  Participants were asked to stand up straight with their back to the wall and 
look directly ahead.  Height was recorded using a stationary stadiometer. 
Total body weight, percentage body fat and percentage fat was measured using 
bioelectrical impedance monitor.  Participants’ height and gender were programmed into 
the monitor; they were then instructed to stand on the scales in their bare feet with their 
heels and balls of their feet in contact with the metal plates, ensuring that their knees were 
not touching. 
Blood pressure was measured using an automated blood pressure cuff.  The cuff of the 
blood pressure monitor was applied securely to the upper section of the left arm.  The 
monitor was then initialised and readings were recorded. 
3.2.3. Standardised Breakfast 
After the blood sample was drawn, participants received a standardised breakfast.  
Participants were supplied with one white bread roll with a choice of butter or margarine 
and jam.  In addition to this participants received a cup of tea or coffee.  As well as 
providing food for participants after their fast this standardised breakfast ensured that all 
participants were in a similar metabolic state before commencing the test. 
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3.2.4. The Contraction Protocol 
Contractions were standardised by using the Bio-Dex Systems 3 Isokinetic Dynamometer 
(Bio-Dex Medical Systems, New York).  Subjects were asked to sit on the dynamometer 
chair with the back of their knees in contact with the chair.  The back of the chair was 
adjusted to hold the subject comfortably in that position. The subjects’ hips, thighs and 
upper body were firmly strapped into position.  In this position their hip angle was held at 
100° angle of flexion.  The chair was raised to the point where the axis of rotation of the 
dynamometer arm was aligned with the lateral femoral condyle.  The lower leg was then 
attached to the lever arm of the dynamometer at a level slightly above the lateral 
malleolus of the ankle joint.  The dynamometer arm was set to hold the leg at 60º of 
flexion during each isometric contraction, with 0° constituting a full extension with a 
straight leg. 
 
Figure 3-1 Protocol set up on the Bio-Dex Systems 3 Isokinetic Dynomometer 
Participants were tested under four different contraction intensities, in the order; 20, 40, 
60 and 80% of the peak value of their maximum voluntary contraction (MVC).  Their 
MVC was established for both legs.  For each test condition the participant was required 
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to carry out 3 isometric contractions for 7 seconds; each contraction was separated by 14 
seconds rest.  During each set of contractions the target force was visible on the Bio-Dex 
monitor.  Participants obtained visual feedback from the Bio-Dex throughout each 
contraction allowing the participant to adjust the force they were required to produce to 
maintain the target force. 
Participants were instructed to perform a contraction by attempting to straighten their leg 
whilst keeping the back of their knee against the Bio-Dex chair.  Each participant 
performed two sets of sub-maximal isometric contractions to warm up the muscle and to 
familiarise them with the protocol before carrying out the MVC.  The first warm up set 
was carried out at 50% of the participants perceived maximum effort; the second warm 
up set was carried out at 75% of their perceived maximum effort.  They were then asked 
to perform one set of maximal voluntary contractions (MVC); all participants were 
encouraged verbally to exert maximal effort during the maximal contraction of both legs.   
During the MVC and the four test contraction intensities the EMG signal was recorded, 
captured and stored on a host computer for future analysis. 
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3.3. Surface Electromyography Technique 
3.3.1. Bio-Pac Equipment 
Surface EMG (sEMG) technique was employed to record and measure both EMG 
amplitude and muscle fibre conduction velocity (MFCV) of the vastus lateralis muscle 
throughout each contraction. 
 
Figure 3-3 BioPac Silver to Silver Chloride Electrodes 
4 silver to silver chloride (Ag-AgCl) EL258S shielded electrodes (Biopac, USA) were 
inserted into a hard plastic mould in a straight line next to one another allowing a distance 
of 12.5mm apart from the signal detection area and configured to record 3 parallel EMG 
signals as described by Lowery et al (2002) (98).  The electrode array, with dry round 
silver inserts, was then positioned on cleansed and shaven skin along the approximate 
pennation angle of the muscle fibres half way between the main belly of the Vastus 
Lateralis and its distal end.  A variety of different locations on the muscle was used until 
there was a clear propagation in one direction of the action potentials without change in 
shape in all of the 3 electromyography (EMG) signal channels.  Then the electrode array 
position was marked with a permanent marker pen, after which the dry silver inserts were 
subsequently removed and the electrode wells were filled with conductive gel (20-30 µl).   
The electrode array was then placed within the marked area on the skin and secured with 
2 sections of Tegaderm.  This electrode array was linked to the BioPac EMG apparatus 
(Biopac Systems, USA) and host computer.  The EMG data was automatically anti-
aliased by the hardware (Biopac Systems, USA).  Each activity was sampled at a 2000 Hz 
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capture rate.  This gave root mean square (RMS) of the EMG signal, giving a measure of 
the power of the signal, which was used for subsequent analyses. 
MFCV was estimated by doing a cross-correlation between the temporal EMG signals 
measured at the three electrodes.  The cross-correlation of two signals x and y is given 
by: 
Rxy(m) = E{xn+my*n}=E{xny*n-m} 
Where E{.} is the expectation operator   The cross-correlation function of two similar 
signals will peak where the two signals are maximally similar.  In our case the signals are 
pulsed signals where one signal is a delayed and path distorted version of the other signal, 
so that their cross-correlation should peak at a number of samples equivalent to the time-
delay between them.  We make use of this property to estimate the delay between the 
signals measured at the electrodes 1 and 2, 2 and 3 and 1 and 3.  With the distance 
between the electrodes known, we found the velocities of the signals from: 
velocitynm = electrode pair distance nm / estimated time delay nm   (m/s) 
MFCV was estimated using the xcorr function of Matlab where xcorr estimates the cross-
correlation sequence of a random process.  The average velocity was then found from the 
velocities V12, V23 and V13.  Estimates of MFCV were accepted only when cross-
correlation values were higher than 0.9. 
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3.4. Analysis of EMG Data 
3.4.1. Analysis of Conduction Velocity from EMG signal 
Two second segment of plateau data was selected.  Wave form data was copied and 
pasted into word pad.  This data was then entered into a specifically designed software 
programme run on the mathematical software Matlab (164).  The software analysed the 
wave form data and established the MFCV of the signal. 
The mat lab programme generated 4 MFCV velocity values.  Values were for electrode 1-
2, 2-3, 1-3 and an average value of the three values.  The average value was utilised for 
analysis.  Where the average value was invalid the value for electrode 1-3 was accepted 
(n=2). 
If the average MFCV for any one contraction was greater than or equal to 30m.s-1 that 
data point was omitted from the study.  A total of 4 control participants were completely 
rejected from the study on this basis.  A further 2 control participants and 2 patients had 
data of one leg rejected.  However; only when data from both legs were rejected was the 
participant completely rejected from the study.  Therefore no data gathered for these 
participants was considered for any analysis within this study. 
3.5. Measurement of Habitual Physical Activity Level 
3.5.1. Accelerometry Data Collection 
Participants were supplied with a uniaxial accelerometer, model GT1M (Actigraph™, 
LLC, Fort Walton Beach, FL).  The GT1M accurately and concisely measures time 
varying acceleration ranging in magnitude from 0.05 to 2.0 G’s (according to 
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manufacturers technical details) in order to measure level of habitual physical activity.  
The actigraph accelerometers were activated and downloaded onto a PC using ActiLife 
Monitoring Systems Software version 3.2.8. 
 
Figure 3-4 GT1M Actigraph™ Accelerometer 
The accelerometer was secured over the participants’ right hip using an elastic belt.  The 
monitor was worn during all waking hours for 7 days, except during water activities (e.g. 
bathing, showering and swimming).  Each accelerometer was set to record activity counts 
in 1 minute epochs (as recommended by manufactures instructions). 
All participants completed a 7-day diary.  Each day participants reported the time they 
attached the accelerometer, time they removed the accelerometer in the evening and 
highlighted any periods of time during the day when the accelerometer was removed (e.g. 
showering). 
3.5.2. Analysis of Accelerometry Data 
Data was rejected if there was less than 480 minutes (8 hours) of activity captured in a 
single day (167).  Where this occurred that single days data was rejected.  
Accelerometery data set was discounted where less than 5 days of valid data was 
collected (167).  Data was downloaded onto the PC and converted into an excel file and 
was split into seven single days worth of data.  The data was screened and any strings of 
zeros of 60 minutes or more were removed (167).  In addition to this data was removed if 
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the participant had indicated in their physical activity log book that they had removed 
their accelerometer.  Total counts for the week and mean counts per day were calculated 
from the data collected. 
3.6. Body Composition Analysis 
3.6.1. Dual-energy X-ray Absorptiometry (DEXA) 
A Whole Body Dual-energy X-ray Absorptiometry (DEXA) scan was carried out on each 
participant.  This scan took place at Yorkhill Children’s Hospital, Glasgow and was 
carried out on a Lunar Prodigy DF+ 13643, GE medical systems.  The DEXA scan 
distinguishes between bone density, fat mass and lean mass.  Participants were asked to 
remove any jewellery containing metal and take off any clothes that contained metal; 
such as jeans with metal zips and button.  Hospital gowns were available for participants 
use.  Participants lay on their back on the base unit and were manoeuvred into position.  
Participants were asked to remain as still as possible throughout the duration of the scan; 
which took between 5-10 minutes.  All scans were carried out by a trained research 
technician who carries out scans regularly. 
3.7. Analysis of Body Composition 
3.7.1. Whole Body 
The default setting was utilised to produce whole body values for total body fat, total 
body lean mass, total body BMD. 
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3.7.2. Thigh 
Using a standard procedure thigh measurements were obtained by custom analysis to 
define each thigh and obtain lean thigh mass (LTM) and Bone Mineral Density (BMD) of 
each thigh.  A standard rectangle was used to mark off the thigh at the point of the greater 
trochanter of the femur and the medial femoral condyle.  The sides of the rectangle were 
altered to incorporate all the mass of the thigh. 
3.8. Statistical Analysis 
3.8.1. Determination of Sample Size 
The sample size was determined using data from a pilot study which compared MFCV 
between MS patients and controls.  Sample size was calculated from estimated size of 
effect from pilot data. 
In addition, a minimum sample size of 35.2 was calculated was using the size formula n = 
2(1-r)N, where N = 800 according to www.sportsci.org and the r value of 0.978 
(P<0.001) was provided by Moritani et al (1993) (114).  The r value for the reliability is 
the reliability of the surface EMG measurement to pick up an accurate reading. 
N= 2(1 – 0.978)800 = 35.2 
Therefore in order to detect a difference between the two groups the study must recruit 36 
subjects. 
As a result we aimed to recruit 40 subjects in total, 20 MS patients and 20 controls 
subjects.  This slightly larger sample size would have accounted for any outliers; 
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equipment failure; lack of attendance from MS patients as a result of the relapsing nature 
of the disease or any unforeseen circumstances. 
3.8.2. Conduction Velocity and Amplitude Data 
All conduction velocity and amplitude data collected for the patient and the control group 
was compared using a multivariate analysis of variance (MANOVA) with repeated 
measures.  Subsequent analysis of MFCV data included percentage thigh fat as a 
covariant.  Significance was accepted at P ≤ 0.05.  Data are expressed as mean ± SD.   
3.8.3. Accelerometry, Blood Sample and DEXA Data 
Data was checked for normality using a histogram with a normal curve to identify any 
discrepancy to the normality of the data.  When normality was assumed an independent 
T-Test was used to compared the patient group to the control group.  Significance was 
accepted at P ≤ 0.05.  Data is expressed mean ± SD. 
 
  
4. Results 
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4.1. Muscle Fibre Conduction Velocity 
4.1.1. Muscle Fibre Conduction Velocity of the Dominant Leg 
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Figure 4-1 Muscle Fibre Conduction Velocity of the Dominant Leg for the Patient and Control 
Group 
Over 20, 40, 60, 80 and 100% MVC 
The patients exhibited a significantly faster (P<0.05) MFCV than controls over all 
contractions 
* Indicate that contractions were not carried out consecutively.  100% contraction was 
carried out first. 
Initial analysis indicated that there was a significant difference in MFCV of the dominant 
leg between patient and control group (P<0.05).  However, a significant difference 
(P<0.05) was also identified in the percentage fat of the dominant thigh between the two 
groups, from which a highly significant positive correlation (P<0.001, r=0.697) was 
observed between percentage fat of the thigh and MFCV.  Therefore, percentage fat of 
the thigh was included as a covariant in the analysis of variance of MFCV of the 
dominant leg between the two groups.  When the covariant was considered in the analysis 
no significant difference (P>0.05) was identified between the two groups. 
Nevertheless, there is a different interaction effect over the contractions from 20-80% 
between the two groups.  MFCV of the control groups incrementally increases from 20% 
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through to 80% of MVC where as the patient group response does not follow this pattern.  
The MFCV of the patient group peaked at 40% of MVC and then decreased again during 
the 60% and the 80% contraction. 
There was no significant difference in MFCV between contraction intensities (P>0.05).  
There was also no interaction identified between the patient and the control group 
(P>0.05). 
Table 4-1 Muscle Fibre Conduction Velocity Values of the Dominant Leg for the Patient and 
the Control Group 
 Contraction Intensity (% of MVC) N Mean MFCV (m.s-1) SD 
20% 12 9.15 6.26 
40% 14 10.21 6.54 
60% 14 11.00 6.57 
80% 14 11.78 6.48 C
on
tro
ls
 
100% (MVC) 14 11.39 6.58 
20% 15 15.75 7.98 
40% 14 18.38 6.49 
60% 13 17.55 7.07 
80% 14 16.84 7.79 P
at
ie
nt
s 
100% (MVC) 15 16.81 7.63 
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4.1.2. Muscle Fibre Conduction Velocity of the Non-Dominant Leg 
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Figure 4-2 Muscle Fibre Conduction Velocity for the Non Dominant Leg of the Patient and the 
Control Group 
Over 20, 40, 60, 80 and 100% MVC 
The patients exhibited a no significant difference (P>0.05) in MFCV compared to the 
control group over all contractions 
* Indicate that contractions were not carried out consecutively.  100% contraction was 
carried out first. 
The initial analysis of the non dominant leg indicated that there was almost a significant 
difference (P=0.054) in the MFCV between the patients and the control groups.  As with 
the dominant leg a significant difference (P<0.05) was found in the percentage fat of the 
non dominant thigh between the groups, from which a highly significant positive 
correlation (P<0.001, r=0.697) was observed between and percentage fat of the thigh and 
MFCV.  Therefore, percentage fat of the non dominant thigh was included as a covariant 
in the analysis of MFCV of the non dominant leg between the groups.  The results found 
that there was no significant difference (P>0.05) in MFCV of the non dominant leg 
between the patient and the control group. 
There was also no significant difference (P>0.05) in MFCV between the contraction 
intensities.  In addition no interaction effect was identified between the patient and the 
control group (P>0.05). 
Results 
 42
Table 4-2 Muscle Fibre Conduction Velocity Values for the Non-Dominant Leg of the Patient 
and the Control Group 
 Contraction Intensity (% of MVC) N Mean MFCV (m.s-1) SD 
20 % 11 7.73 4.65 
40 % 12 7.71 4.31 
60 % 12 8.30 4.28 
80 % 12 9.14 4.49 C
on
tro
ls
 
100 % (MVC) 12 9.08 4.56 
20 % 13 13.81 7.64 
40 % 12 13.30 5.85 
60 % 12 13.27 6.02 
80 % 12 13.88 5.89 P
at
ie
nt
s 
100 % (MVC) 13 13.13 5.86 
4.1.3. Muscle Fibre Conduction Velocity for the Patient Group 
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Figure 4-3 Muscle Fibre Conduction Velocity of the Dominant and Non-Dominant Leg for the 
Patient Group 
Over 20, 40, 60, 80 and 100% MVC 
There was no significant difference (P>0.05) in MFCV between the dominant and non- 
dominant leg of the patient group 
* Indicate that contractions were not carried out consecutively.  100% contraction was 
carried out first. 
There was no significant difference in MFCV between the dominant and non-dominant 
leg of MS patients (P>0.05).  Neither was there a significant difference in MFCV 
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between contraction intensities (P>0.05).  There was no interaction effect identified for 
MFCV between the dominant and non-dominant leg in MS patients (P>0.05). 
Table 4-3 Muscle Fibre Conduction Velocity Values of the Dominant and Non-Dominant Leg 
for the Patient Group 
 Contraction Intensity (% of MVC) N Mean MFCV (m.s-1) SD 
20 % 15 15.75 7.98 
40 % 14 18.38 6.49 
60 % 13 17.55 7.07 
80 % 14 16.84 7.79 D
om
in
an
t 
100 % (MVC) 15 16.81 7.63 
20 % 13 13.81 7.64 
40 % 12 13.30 5.85 
60 % 12 13.27 6.02 
80 % 12 13.88 5.89 
N
on
-D
om
in
an
t 
100 % (MVC) 13 13.13 5.86 
4.1.4. Muscle Fibre Conduction Velocity for the Control Group 
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Figure 4-4 Muscle Fibre Conduction Velocity of the Dominant and Non-Dominant Leg for the 
Control Group 
Over 20, 40, 60, 80 and 100% MVC 
There was no significant difference (P>0.05) in MFCV between the dominant and non- 
dominant leg of the control patient group 
* Indicate that contractions were not carried out consecutively.  100% contraction was 
carried out first. 
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No significant difference in MFCV between the dominant and non-dominant leg of 
control group were identified (P>0.05).  However there was a significant difference in 
MFCV between contraction intensities (P<0.05); indicating that the neuromuscular 
response of the control participant changed as contraction intensity increased.  In addition 
to this these results illustrate that both the dominant and non-dominant legs of the control 
participant exhibit same response to increased contraction intensity; that is the conduction 
velocity increases in both legs in response to increased contraction intensity.  No 
interaction effect was identified when comparing the MFCV of the dominant and non-
dominant leg of control participants (P>0.05) therefore both legs responded in the similar 
way to the increase in contraction intensity. 
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Table 4-4 Muscle Fibre Conduction Velocity Values of the Dominant and Non-Dominant Leg 
for the Control Group 
 Contraction Intensity (% of MVC) N Mean MFCV (m.s-1) SD 
20 % 12 9.15 6.26 
40 % 14 10.21 6.54 
60 % 14 11.00 6.57 
80 % 14 11.78 6.48 D
om
in
an
t 
100 % (MVC) 14 11.39 6.58 
20 % 11 7.73 4.65 
40 % 12 7.71 4.31 
60 % 12 8.30 4.28 
80 % 12 9.14 4.49 
N
on
-D
om
in
an
t 
100 % (MVC) 12 9.08 4.56 
4.2. Amplitude 
4.2.1. Amplitude of the Dominant Leg for the Patient and the Control Group 
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Figure 4-5 Amplitude of the Dominant Leg for the Patient and the Control Group 
Over 20, 40, 60 and 80% of MVC 
There was no significant difference (P>0.05) in amplitude of the dominant leg between 
patient and control participants. 
There was no significant difference in RMS of the dominant leg between patient and 
control participants (P>0.05).  There was however a significant increase in RMS over the 
contraction intensities (P<0.001).  No interaction effect was identified (P>0.05) therefore 
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both patients and controls have shown a similar response throughout the contractions for 
their dominant leg. 
Table 4-5 Amplitude Values of the Dominant Leg for the Patient and the Control Group  
 Contraction Intensity 
(% of MVC) 
N Mean RMS (%) SD 
20% 12 13.27% 3.70% 
40% 14 26.73% 8.39% 
60% 14 41.73% 14.31% C
on
tro
ls
 
80% 14 69.63% 13.75% 
20% 15 21.46% 12.62% 
40% 14 32.75% 16.00% 
60% 13 46.15% 15.81% Pa
tie
nt
s 
80% 14 70.12% 16.66% 
4.2.2. Amplitude of the Non-Dominant Leg for the Patient and the Control 
Group  
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Figure 4-6 Amplitude of the Non Dominant Leg for the Patient and the Control Group 
Over 20, 40, 60 and 80% of MVC 
There was no significant difference (P>0.05) in amplitude of the non -dominant leg 
between patient and control participants. 
There was no significant difference in RMS of the non-dominant leg between the patient 
and control group (P>0.05).  There was however a significant increase in RMS over the 
contraction intensities (P<0.001) in both groups.  Like the dominant leg, this indicates 
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that the non-dominant leg of both patients and controls received more increased neural 
activity as contraction intensity increased; therefore the dominant and non-dominant leg 
exhibited equivalent responses to the increased contraction intensity.  No interaction 
effect was identified (P>0.05) therefore patients and controls have shown similar RMS 
response throughout the contractions of the non-dominant leg. 
Table 4-6 Amplitude Values for the Non Dominant Leg of the Patient and the Control Group 
 
Contraction Intensity 
(% of MVC) 
N Mean RMS (%)  SD 
20% 11 15.36% 5.54% 
40% 12 27.82% 6.78% 
60% 12 43.68% 10.37% C
on
tro
ls
 
80% 12 67.52% 11.57% 
20% 16 17.91% 5.65% 
40% 15 30.98% 10.22% 
60% 15 48.02% 11.58% Pa
tie
nt
s 
80% 15 67.67% 14.62% 
4.2.3. Amplitude of the Patient Group 
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Figure 4-7 Amplitude of the Dominant and Non-Dominant Leg within the Patient Group 
Over 20, 40, 60 and 80% of MVC 
There was no significant difference (P>0.05) in amplitude between the dominant and non-
dominant leg of the patient group. 
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There was no significant difference in RMS between MS patients dominant and non-
dominant leg over all the contractions (P>0.05).  There was nevertheless a highly 
significant increase in RMS between contractions intensities (P<0.001).  This shows that 
both the dominant and the non-dominant leg of MS patients show an increase in neural 
activity received by the muscle as contraction intensity increased.  There was no 
interaction effect identified between the dominant and non-dominant leg in the patient 
group (P>0.05); therefore both leg responded similarly to the increase in contraction 
intensity. 
Table 4-7 Amplitude Values of the Dominant and Non-Dominant Leg within the Patient 
Group 
 
Contraction Intensity 
(% of MVC) 
N Mean RMS (%) SD 
20% 15 21.46% 12.62% 
40% 14 32.75% 16.00% 
60% 13 46.15% 15.81% 
Dominant 
80% 14 70.12% 16.66% 
20% 13 17.91% 5.65% 
40% 12 30.98% 10.22% 
60% 12 48.02% 11.58% 
Non-
Dominant 
80% 12 67.67% 14.62% 
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4.2.4. Amplitude of the Control Group 
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Figure 4-8 Amplitude of the Dominant and Non-Dominant Leg within the Control Group 
Over 20, 40, 60 and 80% of MVC 
There was no significant difference (P>0.05) in amplitude between the dominant and non-
dominant leg of the control group. 
There was no significant difference in RMS between the dominant and non-dominant leg 
of control group (P>0.05).  As seen in the patient group; there was a significant increase 
(P<0.001) in RMS as the contraction force increased within the control group.  There was 
no interaction effect (P>0.05), therefore there was no difference in the RMS response 
throughout the contraction between the dominant and non-dominant leg of the control 
group. 
Table 4-8 Amplitude Values of the Dominant and Non-Dominant Leg within the Control 
Group 
 
Contraction Intensity 
(% of MVC) 
N Mean RMS (%) SD 
20% 12 13.27% 3.70% 
40% 14 26.73% 8.39% 
60% 14 41.73% 14.31% 
Dominant 
80% 14 69.63% 13.75% 
20% 11 15.36% 5.54% 
40% 12 27.82% 6.78% 
60% 12 43.68% 10.37% 
Non-Dominant 
80% 12 67.52% 11.57% 
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4.2.5. RMS Relative to Fat Mass 
Raw RMS data for each contraction was multiplied by the mass of fat in the thigh 
carrying out the contraction.  This analysis reveals whether the higher level of body fat 
apparent in the patient group affected the RMS data. 
 
20 40 60 80 100
0
500
1000
1500
2000
2500
Controls
Patients
Contraction Intensity (% MVC)
R
M
S 
* 
Th
ig
h 
Fa
t (
g)
 
Figure 4-9 RMS relative to Mass of Fat in the Thigh 
Over 20, 40, 60 and 80% of MVC 
There was no significant difference (P>0.05) in RMS*Thigh Fat groups.  There was a 
significant difference (P<0.05) between contraction intensity. 
There was no significant difference (P>0.05) revealed between the groups when 
expressing RMS relative to mass of fat in the thigh.  However there was a significant 
difference (P<0.05) between contraction intensity as had previously been elucidated from 
the percentage RMS data.  A similar result emerged between the dominant and non 
dominant legs.  Data is shown in tables below. 
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Table 4-9 Patients RMS * Thigh Fat Data 
  N 
Mean 
RMS*Thigh 
Fat(g) 
SD 
20% 15 188.61 156.31 
40% 14 326.68 254.78 
60% 13 516.67 339.15 
80% 14 748.59 436.65 D
om
in
an
t 
100% 15 1071.20 661.31 
20% 13 141.75 61.29 
40% 12 281.28 197.76 
60% 12 490.92 498.43 
80% 12 703.83 713.03 
N
on
-D
om
in
an
t 
100% 13 942.38 733.87 
 
Table 4-10 Controls Patients RMS * Thigh Fat Data 
  N 
Mean 
RMS*Thigh 
Fat(g) 
SD 
20% 11 170.56 78.26 
40% 12 400.61 290.89 
60% 12 622.88 485.21 
80% 12 1034.09 609.93 D
om
in
an
t 
100% 12 1458.12 860.14 
20% 10 203.96 104.43 
40% 11 342.60 173.16 
60% 11 541.99 310.78 
80% 11 830.21 486.94 
N
on
-D
om
in
an
t 
100% 11 1224.33 634.44 
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4.3. Torque Production 
4.3.1. Performed Contraction Intensity 
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Figure 4-10 Intensity of Contraction Performed at each Target Intensity 
Over 20, 40, 60 and 80% of MVC 
There was no significant difference in performed contraction intensity within the patient 
(P>0.05) or the control (P>0.05) group 
There was no significant difference in performed contraction intensity within the patient 
(P>0.05) or the control (P>0.05) group when comparing the dominant and non-dominant 
leg within each group at each contraction intensity.  Neither was there a significant 
difference in performed contraction intensity between the patient and the control groups 
for the dominant leg (P>0.05) or the non-dominant leg (P>0.05) at each contraction 
intensity. 
There was a highly significant difference between the contraction intensities when 
compared between groups and between dominant and non-dominant leg (P<0.001).  
Therefore, each target contraction was carried out at significantly different intensities 
than the other target intensity in both groups.  This was the intended outcome as the 
purpose of the study was to investigate neuromuscular characteristics at different 
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contraction intensities.  This proves that the contractions were in fact carried out at 
increasing intensity. 
However, there was a significant difference when performed contraction intensity was 
compared to target intensity for the dominant (P<0.05) and non-dominant (P<0.05) leg.  
There was a highly significant difference in performed contraction intensity and target 
contraction intensity for both the patient (P<0.001) and the control (P<0.001) group.  
Consequently the performed contraction was carried out at a significantly different 
intensity to the intended contraction intensity however there was no significant difference 
in the contraction intensity carried out between the two groups or between the dominant 
and non dominant leg within each group therefore comparison of the results remains 
valid. 
Table 4-11 Intensity at which Target Contractions were Performed 
  
Target Contraction Intensity 
(% of MVC) 
N 
Actual Mean Contraction 
Intensity 
(% of MVC) 
SD 
20 % 15 28.24% 8.32% 
40 % 14 44.54% 3.77% 
60 % 13 62.79% 2.98% 
D
om
in
an
t 
80 % 14 81.58% 4.62% 
20 % 13 30.03% 12.42% 
40 % 12 43.98% 3.47% 
60 % 12 63.13% 5.49% 
Pa
tie
nt
s 
N
on
-D
om
in
an
t 
80 % 12 80.88% 8.16% 
20 % 12 24.34% 4.93% 
40 % 14 42.10% 2.97% 
60 % 14 62.20% 3.48% 
D
om
in
an
t 
80 % 14 81.47% 2.28% 
20 % 11 23.82% 3.79% 
40 % 12 42.10% 2.50% 
60 % 12 61.50% 2.85% 
C
on
tro
ls
 
N
on
-D
om
in
an
t 
80 % 12 81.79% 2.52% 
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4.3.2. Absolute Torque - Maximum Voluntary Contraction (MVC) 
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Figure 4-11 Maximum Voluntary Contraction of the Patient and Control Group 
Maximum torque produced during participants MVC for both legs 
The MVC of the control group was significantly greater (P<0.05) than the MVC of the 
patient group for both legs. 
The MVC of the control group was significantly greater than the MVC of the patient 
group when comparing the dominant (95% CI 3.67, 79.20; P<0.05) and non-dominant 
(95% CI 7.31, 82.56; P<0.05) leg.  The control group produced significantly more torque 
with both their dominant and non-dominant leg than the patient group.  Therefore the 
control group exhibited greater torque production than the patient group for both legs. 
Table 4-12 Maximum Voluntary Contraction for the Dominant and Non-Dominant Leg of both 
Groups 
 Groups N Mean Force Produced (N.M) SD 
Controls 14 175.09 43.94 
Dominant 
Patients 15 133.65 54.20 
Controls 12 160.14 47.55 Non-
Dominant Patients 13 115.21 43.41 
There was no significant difference between dominant and non-dominant leg in the 
patient (95% CI -20.12, 57.01; P>0.05) or the control (95% CI-22.09, 52.00; P>0.05) 
group.  Hence within each group the dominant leg was not significantly stronger than the 
non-dominant leg. 
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4.3.3. Relative Torque 
Relative torque was used to express the torque produced in terms of muscle mass.  
Therefore this analysis indicates how much torque each gram of muscle produced during 
the MVC.  This allows a more direct comparison of muscle quality to be made between 
the groups (100). 
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Figure 4-12 Relative Torque Production in the Patient and Control Group 
Torque produced per gram of muscle mass during participants MVC with both legs 
There was no significant difference (P>0.05) in torque production per gram of muscle 
between groups. 
There was no significant difference in torque production per gram of muscle between 
groups for the dominant (95% CI -0.0007, 0.0073; P>0.05) and the non-dominant (95% 
CI -0.0010, 0.0068; P>0.05) leg. 
The torque produced per gram of muscle in the dominant leg is not significantly different 
from that produced in the non dominant for both the patient (95% CI -0.0008, 0.0064; 
P>0.05) and the control (95% CI -0.0012, 0.0075; P>0.05) group. 
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Table 4-13 Relative Torque Production in the Patient and Control Group 
 Groups N Mean SD 
Controls 14 0.026 0.0076 
Dominant 
Patients 15 0.024 0.0048 
Controls 11 0.024 0.0047 
Non Dominant 
Patients 13 0.021 0.0045 
4.3.4. Absolute Lean Mass of the Thigh 
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Figure 4-13 Absolute Lean Mass of Thigh for both Patient and Control Group 
Lean mass of both legs considered within each group 
A significant difference (P<0.05) was identified between the groups when the lean thigh 
mass of both the dominant and the non dominant leg were considered within each group. 
There was no significant difference in absolute LTM when comparing solely the 
dominant (95% CI -408, 2231: P>0.05) or the non dominant (95% CI -2487, 425: 
P>0.05) leg between groups.  A significant difference was identified between the groups 
when the lean thigh mass of both the dominant and the non dominant leg were considered 
within each group (95% CI -1899, -34.86; P<0.05). 
In addition, no significant difference was identified between the dominant and non 
dominant leg within the patient group (95% CI -1249, 1454; P>0.05) or the control (95% 
CI -1420, 1386; P>0.05) group. 
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4.3.5. Relative Lean Mass of the Thigh – Between Groups Comparison 
Lean Thigh Mass (LTM) ratio is used to express the lean mass of the thigh in comparison 
to the lean mass of the whole body.  This allows the lean mass of the thigh to be 
expressed as a relative percentage of the whole body lean mass. 
Table 4-14 Lean Thigh Mass – Between Groups Comparison 
§ LTM Ratio: LTM (Lean Thigh Mass)/LBM (Lean Body Mass)*100 
* Calculation includes mass of both thighs. 
† Mass of one thigh considered in these calculations 
Lean Thigh Mass Ratio § Controls  Patients  P Value 
 Mean LTM (%) N Mean LTM (%) N  
Total * 24.80±1.51 12 23.72±1.51 15 0.077 
Dominant Leg † 12.37±0.79 12 11.86±0.79 15 0.103 
Non-Dominant Leg † 12.43±0.86 12 11.86±0.88 15 0.108 
No significant difference was identified in LTM ratio between the patient and control 
group for either dominant (95% CI -0.001, 0.11; P>0.05) or non-dominant leg (95% CI -
0.001, 0.013; P>0.05).  However the difference in LTM ratio when considering total lean 
thigh mass; which includes the mass of both the dominant and non-dominant thigh 
together, is approaching significance (95% CI -0.001-0.023; P=0.077). 
4.3.6. Relative Lean Mass of the Thigh – Within Group Comparison 
Table 4-15 Lean Thigh Mass – With Group Comparison 
 Dominant Non-Dominant  
 Mean LTM (%) N Mean LTM (%) N P Value 
Controls 12.37±0.79 12 12.43±0.86 12 0.878 
Patients 11.86%±0.79 15 11.86±0.88 15 0.976 
There is no significant difference between dominant and non-dominant leg for the LTM 
ratio within the control (95% CI -0.008-0.006; P>0.05) or the patient (95% CI -0.006-
0.006; P>0.05) group.  This is in concurrence with the finding that there was no 
significant difference in the MVC between the dominant and non-dominant leg within the 
patient and control group. 
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4.3.7. Correlation of MFCV to Lean Thigh Mass Ratio 
LTM of the dominant leg was correlated against MFCV from the 100% contraction 
(MVC) of the dominant leg for each participant; and likewise for the non dominant leg.  
Then both groups were considered together for both the dominant and the non dominant 
leg. 
Table 4-16 Correlation of MFCV to Lean Thigh Mass Ratio 
* Significance P<0.05 
Lean Thigh Mass N r P  
Patients 15 -0.144 0.610 Fig 4-16 
Controls 12 -0.629 0.028* Fig 4-14 Dominant  
Both Groups 27 -0.400 0.039* Fig 4-15 
Patients 13 -0.241 0.428  
Controls 11 -0.457 0.158  Non-Dominant 
Both Groups 24 -0.395 0.056  
A negative correlation was revealed throughout all of the correlations made regarding 
LTM ratio and MFCV; which indicated that as lean thigh mass ratio increased MFCV 
decreased.  The comparison reached significance (P<0.05) in two circumstances (Table 4-
16); when considering the dominant leg of both groups (Fig 4-15) and when considering 
the control groups (Fig 4-14) dominant leg.  Figure 4-16 shows that there is no 
correlation between MFCV and Lean Thigh Mass Ratio. 
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Figure 4-14 Correlation of MFCV to Lean Thigh Mass ratio for the Dominant Leg of the 
Control Group  
3,000 4,000 5,000 6,000 7,000 8,000 9,000 10,000 11,000-2.5
2.5
7.5
12.5
17.5
22.5
27.5
r = -0.400
P = 0.039
LTM (g)
M
FC
V
 (m
.s
-1
)
 
Figure 4-15 Correlation of MFCV to Lean Thigh Mass Ratio of the Dominant Leg of Both 
Groups 
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Figure 4-16 Correlation of MFCV to Lean Thigh Mass Ratio of the Dominant Leg of the Patient 
Groups 
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4.4. Body Composition Analysis 
4.4.1. Total Percentage Body Fat 
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Figure 4-17 Total Body Fat (%) of Patients and Controls 
The patient group exhibited a significantly higher (P<0.05) percentage total body fat than 
the control group. 
* Denotes significant difference 
Figure 4-17 shows that there was a significant difference in total body fat percentage 
between the patient group and the control group (95% CI -0.139, -0.0140; P<0.05). 
4.4.2. Correlation of MFCV to Total Body Fat Percentage 
Total body fat percentage for each participant was correlated with the MFCV from their 
MVC for both legs. 
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Table 4-17 Correlation of MFCV to Total Percentage Body Fat 
* Significance P<0.05 
  N r P  
Patients 15 0.516 0.049* Fig 4-18 
Controls 12 0.526 0.079  Dominant  
Both Groups 27 0.564 0.002* Fig 4-19 
Patients 13 0.394 0.178  
Controls 11 0.398 0.231  Non-Dominant 
Both Groups 24 0.437 0.033* Fig 4-20 
The relationship between total percentage body fat and MFCV shows a positive 
correlation throughout all comparisons (Table 4-17); this signifies that as the participants’ 
level of body fat increased so did their MFCV.  A significant (P<0.05) correlation was 
identified when considering the dominant leg of the patient group (Fig 4-18), the 
dominant leg of both groups (Fig 4-19) and the non dominant leg of both groups (Fig 4-
20). 
This correlation may indicate a physiological response to the increased level of body fat 
however it may also be a methodological problem as increased levels of adipose tissue 
are known to artificially increase the MFCV reading from surface electrodes (110). 
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Figure 4-18 Correlation of MFCV to Total Percentage Body Fat for the Dominant Leg of the 
Patient Group 
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Figure 4-19 Correlation of MFCV to Total Percentage Body Fat for the Dominant Leg of both 
Groups 
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Figure 4-20 Correlation of MFCV to Total Percentage Body Fat of the Non-Dominant Leg of 
both Groups 
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4.4.3. Percentage Fat of the Thigh 
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Figure 4-21 Percentage Fat of the Dominant Thigh for the Patient and the Control Group 
The patient group exhibited a significantly higher (P<0.05) percentage fat of the thigh 
than the control group. 
* Denotes significant difference between dominant legs. 
** Denotes significant difference between non dominant legs. 
A significant difference in percentage fat of the thigh of the dominant leg was identified 
between the patient and the control group; (95% CI 0.02569, 0.16231; P<0.05). 
A significant difference in percentage fat of the thigh of the non dominant leg was 
identified between the patient and the control group; (95% CI 0.02622, 0.17792; P<0.05). 
Table 4-18 Percentage Fat of the Dominant Thigh for the Patient and the Control Group 
   N Mean Fat (%) SD 
Dominant 12 34.28 9.64 
Control 
Non Dominant 11 34.25 10.34 
Dominant 15 43.83 7.22 
Patient 
Non Dominant 13 44.46 7.54 
In addition there was no significant difference in percentage fat of the thigh between the 
two legs within the control (95% CI -8.63, 8.63; P>0.05) and the patient (95% CI -6.37, 
5.11; P>0.05) group. 
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Figure 4-22 Percentage Fat of the Thigh when considering both the Dominant and Non-
Dominant Leg within each Group 
The patient group exhibited a highly significantly higher (P<0.001) percentage fat of the 
thigh than the control group. 
* Denotes significant difference. 
A highly significant difference in percentage fat of the thigh was identified between the 
groups when considering both the dominant and non dominant leg together within each 
group; (95% CI 0.05069, 0.14642; P<0.001). 
4.4.4. Correlation of MFCV to Percentage Fat of the Thigh 
Percentage fat of the thigh for each participant was correlated against their MFCV from 
their 100% contraction (MVC).  Both the dominant and the non dominant leg were 
considered in both the patient and the control group. 
Table 4-19 Correlation of MFCV to Percentage Fat of the Thigh 
*Significance P<0.05 
**Significance P<0.001 
 N r P  
Patients 28 0.532 0.004* Fig 4-23 
Controls 23 0.795 <0.001** Fig 4-24 
Both Groups 51 0.0697 <0.001** Fig 4-25 
A positive correlation existed between MFCV and percentage fat of the thigh when 
considering patient and controls alone and when considering both groups together; all 
three correlations were significant.  A highly significant (P<0.001) correlation was 
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identified when looking at the correlation between MFCV and percentage fat of the thigh 
of the control group and for both groups together.  A significant correlation was identified 
when looking at the relationship between patients MFCV and patients’ thigh fat. 
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Figure 4-23 Correlation of MFCV to Percentage Fat of the Thigh in the Patient Group 
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Figure 4-24 Correlation of MFCV to Percentage Fat of the Thigh in the Control Group 
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Figure 4-25 Correlation of MFCV to Percentage Fat of the Thigh in both the Patient and the 
Control Group 
4.4.5. Bone Mineral Density – Between Groups Comparison 
Table 4-20 Bone Mineral Density – Between Groups Comparison 
 Controls Patients  
 
Mean BMD 
(g/cm2) 
SD N Mean BMD (g/cm2) SD N P value 
Whole Body 1.185 0.132 12 1.144 0.136 15 0.476 
Dominant  1.381 0.166 12 1.289 0.212 15 0.234 
Non-Dominant 1.394 0.151 12 1.275 0.235 15 0.141 
There was no significant difference in BMD between patient and control group for either 
whole body (95% CI -0.08, 0.16; P>0.05), dominant (95% CI -0.06, 0.25; P>0.05) or 
non-dominant (95% CI -0.04, 0.28; P>0.05) thigh. 
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4.4.6. Bone Mineral Density – Within Group Comparison 
Table 4-21 Bone Mineral Density – Within Groups Comparison 
  Dominant  Non-Dominant   
 N Mean BMD (g/cm2) SD Mean BMD (g/cm2) SD P value 
Controls 12 1.381 0.166 1.394 0.151 0.841 
Patients 15 1.289 0.212 1.275 0.234 0.862 
There was no significant difference in BMD between dominant and non dominant leg for 
either the control (95% CI -0.15, 0.12; P>0.05) or the patient (95% CI -0.15, 0.18; 
P>0.05) group.  This result supports previous findings in this study to suggest that there 
are no differences between the dominant and non-dominant leg for other variables such as 
LTM and percentage fat of the thigh. 
4.5. Physical Activity Levels 
4.5.1. Total Physical Activity 
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Figure 4-26 Total Physical Activity Counts for the Patient and the Control Group 
The patient group was significantly (P<0.05) less active than the control group 
* Denotes significant difference. 
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The control group show significantly higher total counts than the patients group (95% CI 
60944.46, 237682.7 P<0.05).  This demonstrates that control group exhibited a 
significantly higher level of habitual physical activity than the patient group. 
4.5.2. Relationship of MFCV to Total Physical Activity 
Total physical activity counts for each participant were correlated to their MFCV from 
the 100% contraction (MVC) of both the dominant and non-dominant leg. 
Table 4-22 Correlation of MFCV to Total Physical Activity Counts 
** Significance P<0.001 
Total Physical Activity N r P  
Patients 14 -0.106 0.718  
Controls 13 0.014 0.964  Dominant  
Both Groups 27 -0.254 0.202  
Patients 12 0.826 0.001** Fig 4-27 
Controls 12 0.005 0.987  Non-Dominant 
Both Groups 24 0.180 0.399  
The correlation of MFCV to total physical activity was not consistent throughout all 
comparisons.  Two of the comparisons exhibited a negative correlation (Table 4-22) 
suggesting that as total physical activity level increased MFCV decreased, although this 
correlation did not reach significance.  Whereas the other four comparisons reveal a 
positive correlation signifying that as total physical activity level increased so did MFCV.  
This correlation reached significance in one instance (P=0.001); Figure 4-27 shows how 
total physical activity level increased and MFCV increased when the non-dominant leg of 
the patient group was correlated to total physical activity level of the patient group. 
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Figure 4-27 Correlation of MFCV to Total Physical Activity for Patients with the Non-Dominant 
Leg 
4.5.3. Mean Physical Activity 
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Figure 4-28 Mean Average Counts/Day for the Patient and the Control Group 
The patient group was significantly (P<0.05) less active than the control group 
* Denotes significant difference. 
The control group show a significantly higher mean average counts per day than the 
patient group (95% CI 54.35, 261.87; P<0.05).  This substantiates the findings from the 
total physical activity level results; that the control group show evidence of a higher level 
of habitual physical activity than the patient group. 
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4.5.4. Correlation of MFCV to Mean Physical Activity 
Mean physical activity counts for each participant was correlated to their MFCV from the 
100% contraction (MVC) of both the dominant and non-dominant leg 
Table 4-23 Correlation of MFCV to Mean Physical Activity Counts 
* Significance P<0.001 
Mean Physical Activity N r P  
Patients 14 -0.096 0.743  
Controls 13 0.023 0.942  Dominant  
Both Groups 27 -0.227 0.256  
Patients 12 0.834 0.001* Fig 4-29 
Controls 12 0.048 0.882  Non-Dominant 
Both Groups 24 0.235 0.269  
When taking into consideration mean physical activity, similar findings to the correlation 
between total physical activity and MFCV were revealed.  A negative correlation was 
exposed when the correlation was made between dominant leg of both the groups 
together as well as for the patient group alone.  This suggests that the MFCV decreased as 
mean physical activity level increased; however this correlation did not reach 
significance.  The further four correlation made between mean physical activity level and 
MFCV exhibited a positive correlation suggesting that as mean physical activity level 
increased so did MFCV.  Three out of the four correlations show a very weak positive 
relationship where as one comparison reached significance. 
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Figure 4-29 Relationship of MFCV to Mean Physical Activity for patients for the Non-Dominant 
Limb 
4.6. Blood Sample Results 
4.6.1. Blood Lipid Profile 
Table 4-24 Blood Lipid Profile Results for the Patient and the Control Group 
  Control Group   Patient Group   
 N 
Mean 
Concentration 
(mmoll-1) 
SD N 
Mean 
Concentration 
(mmoll-1) 
SD P Value 
Cholesterol 17 5.18 1.04 14 5.30 0.61 0.715 
Triglyceride 17 1.30 0.42 14 1.25 0.48 0.798 
HDL 17 1.45 0.37 14 1.43 0.33 0.880 
cLDL 17 3.13 0.92 14 3.29 0.73 0.615 
There was no significant difference identified between the patient and control group for 
cholesterol (95% CI -0.52635, 0.75761; P>0.05), triglycerides (95% CI -0.37143, 
0.28824; P>0.05), HDL (95% CI -0.28253, 0.24337; P>0.05) or calculated LDL (95% CI 
-0.46664, 0.77597; P>0.05) levels. 
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4.6.2. Vitamin D Concentration 
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Figure 4-30 Vitamin D Concentration of the Patient and the Control Group 
The patient group exhibited significantly (P<0.05) lower vitamin D levels that the control 
group. 
* Denotes significance 
There was a significant difference in serum Vitamin D concentration between the patient 
and the control group (95% CI -33.49702, -2.18365; P<0.05). 
Table 4-25 Vitamin D Concentration of the Patients and the Control Group 
 N 
Mean Vitamin D Concentration 
(mmoll-1) SD 
Controls 17 59.41 21.38 
Patients 14 41.57 20.98 
MS patients exhibit a significantly lower level of serum vitamin D than the control group. 
 
  
5. Discussion 
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5.1. Study Objectives 
Aim:  The aim of this study was to describe the neuromuscular characteristics of Multiple 
Sclerosis (MS) patients.  To help explain the neuromuscular characteristics physical 
activity levels, body composition and blood lipid profile were measured.  In addition, 
Vitamin D was measured to determine if this was deficient in MS patients. 
Hypothesis:  We hypothesised that muscle fibre conduction velocity (MFCV) would be 
elevated and amplitude would be impaired in Multiple Sclerosis patients compared to an 
age and sex matched control group.  In addition, we hypothesised that physical activity 
levels would be reduced, body composition would exhibit a higher percentage fat, blood 
lipid profile would be less favourable and Vitamin D levels would be reduced in the 
group of MS patients. 
5.2. Adherence to Protocol 
5.2.1. Comparable Groups 
The patient and the control group were well matched; there was no difference between 
the groups in age, sex, height, weight or BMI.  There were also an equivalent number of 
males and females in each group. 
Data generated from the present study confirms that the two groups were well matched.  
The blood sample results show that the groups were well matched because there was no 
difference in blood lipid profile between the groups.  If blood lipid profile can be taken as 
an indication of health status both groups are equivalent for risk of various medical 
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conditions such as coronary heart disease, obesity and type 2 diabetes.  It also indicates a 
similarity in lifestyle between the two groups. 
Physical activity results, although they show a significant difference between the groups, 
the absolute values from both the groups remain relatively low.  Hence the control group 
were a relatively sedentary group; therefore there were no participants in the group who 
are highly active who could potentially skew the results. 
5.2.2. MS Patients’ Disability Status 
All patients had a positive diagnosis of MS and had been diagnosed for a minimum of 3 
years.  The disability status of patients ranges between 4 and 6 on the expanded disability 
status scale (92).  All patients presented with a degree of disability in the lower 
extremities.  All patients completed the contraction protocol apart from one person who 
was unable to carry out the contraction with one of their legs.  The leg that was used to 
carry out the contractions was considered the dominant leg for analysis. 
5.2.3. Contraction Protocol 
The contractions within the protocol were carried out at 20%, 40%, 60% and 80% of 
participants MVC.  The target contraction intensities were calculated from each 
individual MVC; this was calculated for each leg.  As the participants contracted their leg 
they received visual feedback, from a PC monitor, on how closely they maintained the 
force to their target contraction intensity, which was indicated on the screen.  They were 
encouraged to adjust their contraction in line with the visual feedback in order to return to 
the target intensity indicated on the screen. 
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There was no difference in performed contraction intensity when comparing the dominant 
and non-dominant leg within each group.  Neither was there a difference in performed 
contraction intensity between the patient and the controls groups for the dominant leg or 
the non-dominant leg.  This reaffirms that the study was well controlled and highlights 
that comparisons made between the groups and within the groups are valid as no 
significant differences exists between the groups or within the groups for the relative 
contraction intensity. 
There was a difference in contraction intensity between the target contraction intensities 
when compared between groups and within groups.  Therefore, each contraction was 
carried out at a different intensity to the other contractions. In addition, within each 
contraction intensity i.e. (40%) the intensity carried out was not different between groups 
or within groups.  This shows that comparison of individual contraction intensity between 
the two groups is valid as no difference in contraction intensity was identified between 
groups. 
However, there was a difference when performed contraction intensity was compared to 
target intensity for the dominant and non-dominant leg.  There was also a difference in 
performed contraction intensity and target contraction intensity for both the patient and 
the control group.  Consequently the performed contractions were carried out at a 
different intensity than was intended.  However, there was no difference in the 
contraction intensity carried out between the two groups or between dominant and non-
dominant legs, therefore comparisons can still be made. 
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5.2.4. Vastus Lateralis 
In the present study the vastus lateralis (VL) was measured in all patients regardless of 
what symptoms they presented with.  This may have underestimated the degree of 
difference in MFCV between patients and controls as VL is not necessarily affected by 
the disease.  Therefore, had the affected area of each patient been measured and 
compared to the equivalent muscle of a controls subject this may have shown more of a 
difference. 
Nevertheless, it is the norm for patients with MS to experience some form of impaired 
gait and therefore it was assumed that using the vastus lateralis muscle, which is used for 
locomotion, as a means of comparison was as valid as any.  In addition the vastus 
lateralis tends to be situated closer to the surface of the skin than other quadriceps muscle 
and therefore was more easily identifiable.  This was also an advantage as the electrodes 
were more likely to make direct contact with the muscle. 
5.3. Neuromuscular Characteristics 
5.3.1. Muscle Fibre Conduction Velocity 
The primary aim of this study was to identify if neuromuscular characteristics were 
different in MS patients compared to age and sex matched control participants.  Initial 
findings indicated that the MFCV was faster in the patient group than it was in the control 
group; this difference reached significance when comparing the dominant leg of the two 
groups and just missed significance when comparing the non dominant leg.  This 
suggests altered neuromuscular characteristics in the MS group as it may indicate a 
predominance of type 2 fibres within the muscle as a result of disuse (165; 166) or as a 
consequence of MS (82).  However a significant difference was also revealed for the 
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dominant and the non dominant leg when comparing percentage fat of the thigh between 
groups.  A highly significant (P<0.001, r=0.697) positive correlation was also observed 
when MFCV was related to percentage fat of the thigh.  This indicates that as the level of 
body fat increased the MFCV rate was increased.  High levels of body fat have 
previously been shown to artificially elevate the MFCV signal (110).  Therefore 
percentage fat of the thigh was added into the analysis as a covariant.  Once the 
comparison was adjusted to take account of the effect of body fat no significant 
differences existed between groups for either the dominant or the non dominant leg.  
Therefore the difference apparent in the initial comparison seemed to be as a consequence 
of the participants’ body fat rather than as a result of altered neuromuscular 
characteristics.  However a difference in the response of the MFCV to the increase in 
contraction intensity was noted between the groups.  While the MFCV of the control 
group continued to increase with each increment of intensity the MFCV of the patients 
group did not.  Therefore additional variables are affecting the MFCV of the patient.  
This may be evidence of an increased proportion of type 2 fibres within the muscle fibres 
of MS patients.  As the MFCV of the patients was elevated during the lower intensity 
contractions this suggests that the MS patients were recruiting type 2 fibres during the 
lower intensity contractions.  This insinuates that MS patients may express more type 2 
fibres within the muscle and hence these are the only fibres available for recruitment. 
There was no significant difference in MFCV over the contraction intensities when 
comparing the dominant or the non dominant leg between the two groups.  This therefore 
suggests that there was no alteration in neuromuscular response to increased torque 
production between the groups.  However, when MFCV over the contraction was 
compared between legs within each group a significant difference was revealed within 
the control group but not in the patient group.  Therefore differences in MFCV between 
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the contractions were detected in the control group but not the patient group.  This may 
indicate a methodological problem with EMG data collection from the patient group.  As 
mentioned previously findings from the present study show that patients have a higher 
percentage of fat around the thigh than control participants.  It has been documented 
(110) that high level of subcutaneous fat can artificially elevated the MFCV reading 
thereby making the signal less sensitive to picking up any alteration of the signal.  
Previous research by Nielson et al (2007) (124) has also demonstrated that alteration is 
MFCV are less detectable the further away the electrode is situated from the innervation 
zone.  In the present study the electrode was placed midway between the innervation zone 
and the distal tendon however in some cases it was necessary to move the electrode closer 
to the distal tendon in order to receive a signal.  In doing so, according to Neilson et al 
(2007) we may have moved the electrode too far away from the innervation zone to 
detect any differences over contraction intensity.  It is interesting that in the control group 
where the percentage fat of the thigh was lower than the patients, a difference in MFCV 
over the contraction was detected. 
The difference observed over the contraction in the control group would indicate that as 
torque production increased MFCV increased.  It is well accepted that when higher 
intensity contractions are required a greater proportion of type 2 muscle fibres are 
recruited (70; 113).  It is also known that type 2 muscle fibres carry the electrical signal 
along the sarcolemma more quickly than type 1 fibres (5).  Therefore an increase in 
MFCV in response to increased torque production indicates that more type 2 muscle 
fibres are being recruited. 
There was no difference over the contraction in the patient group.  This may be as a 
consequence of reduced sensitivity of the EMG technique because of the high level of fat 
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in the patient group.  However it may also be a physiological response as research has 
shown (82) that MS patients exhibit a higher proportion of type 2 muscle fibres than 
control participants.  Consequently, MS patients will inadvertently recruit type 2 fibres at 
lower contractions therefore MFCV will be higher at lower intensities.  As contraction 
intensity increases more muscle fibre will be recruited, however the fibres that remain to 
be recruited will also be type 2 fibres therefore although more fibres are recruited there is 
no shift in recruitment from type 1 to type 2 hence the MFCV would not change as torque 
production increases. 
In addition there is no significant difference between the dominant and non dominant leg 
within the patient or the control group.  There was a similar neuromuscular response to 
the contraction intensities between the dominant and non dominant leg within each group.  
This would be expected in the control group however it is surprising in the patient group 
as MS tends to affect one side of the patient more than the other.  This may, in part, be as 
a consequence of the elevated percentage fat of the thigh in the patient group.  The layer 
of fat may have dampened the signal and as a result discrete differences within the 
muscle may have gone unnoticed. 
Therefore, the MFCV results indicate that there were no differences in the neuromuscular 
characteristics of MS patients when compared to an age and sex matched control group.  
The MFCV rate changes in response to peripheral changes, such as change in distribution 
of muscle fibre type (26), muscle temperature (64), fatigue (148) and contraction 
intensity (168; 169); therefore unaltered MFCV between patients and controls indicates 
that no peripheral differences exist between the groups. 
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5.3.2. Amplitude – Root Mean Square (RMS) 
The root mean square (RMS) is the measure of global motor unit recruitment and 
therefore is indicative of the neural activity received by the muscle from the central 
nervous system (110).  There was no difference in RMS between the patient and the 
control group for the dominant and the non dominant leg throughout the contractions.  
These results indicate that there is no difference in neuromuscular recruitment strategies 
between the patient and the control group.  As RMS is indicative of the neural activity 
received by the muscle from the CNS the results signify that there is no difference in the 
functional capacity of the CNS between the two groups. 
There was no difference in RMS between the dominant and non dominant leg within each 
group.  These results support the previous finding of the present study which shows that 
there is no difference in MFCV between the dominant and non dominant leg within each 
group. 
In addition, RMS data was expressed relative to grams of fat within the thigh.  This 
analysis was carried out as fat has a low pass filtering effect on the RMS data (110).  The 
findings revealed no difference between the patient and the control group when 
multiplying the RMS by grams of fat in the thigh.  This indicates that both groups were 
affected by the low pass filtering effect of fat to the same extent.  However this analysis 
did show a significant difference between the contraction intensity as had previously been 
demonstrated by the percentage RMS data. 
These findings add credence to the MFCV finding as the present RMS results indicate 
that similar amounts of neural activity is being received by both legs within each group 
and between the two groups.  Therefore, it would be reasonable to expect similar 
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neuromuscular characteristics between the two groups as previous research has indicated 
that neural activity dictates phenotypic expression in mammalian muscle (133).  The 
MFCV and RMS results from the present study support this contention.  However, the 
RMS proves that the CNS is capable of delivering equivalent amounts of neural activity 
to the muscle for an equivalent relative intensity contraction.  What the RMS cannot 
indicate is how much neural activity the muscle does receive or has received over time   
The neural activity received by the muscle over time dictates the characteristic of the 
muscle (133).  If the nature or amount of neural activity received by the muscle changes 
then the characteristics of the muscle will adapt in response altered innervation (133). 
The greatest way to increase the amount of neural activity reaching a muscle is to 
increase the level of physical activity.  The present study measured physical activity and 
showed that the level of habitual physical activity was reduced in the patient group.  
Therefore this suggests that less neural activity is being received by muscles of the MS 
groups than the control group.  It has been shown that muscle responds to reduced 
innervation by reverting to type 2 muscle fibres (28; 101; 133; 165; 166).  It has been 
shown that any innervation regardless of the nature of the innervations influences a shift 
in fibre type from type 2 to type 1 (133).  Although the physical activity results show a 
difference in the activity levels between the groups the effect of the difference in physical 
activity levels were not apparent in the MFCV or the RMS findings.  Perhaps the 
difference in physical activity was not enough.  Even though the difference reached 
statistical significance it may not have reached physiological significance.  Although a 
difference was detected between the groups both groups would be considered to be 
sedentary.  Therefore, neither group was completely inactive nor neither group was 
highly active, therefore no extreme conditions had been placed on the muscle.  This may 
explain why no differences in MFCV or RMS were detected. 
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There was a highly significant difference in the RMS between the contraction intensities 
in both groups however no interaction was identified between the groups.  Both groups 
show similar RMS responses to the increase in contraction intensity, this indicates that 
the amount of neural activity leaving the CNS for each contraction is no different 
between the two groups.  Therefore, patients with relatively mild MS (4-6 EDSS) 
maintain the ability to voluntarily generate torque throughout the full range of contraction 
intensities. 
Patients exhibited the same amplitude response as the control group over all the 
contractions.  This is interesting as it shows that patients are as capable at carrying out 
low level contraction as they are at high level contractions.  In MS patients the lesions on 
the neurons in the CNS make it more difficult for the electrical signal to be transmitted 
past the point of the lesion (154).  The bigger the lesion the more actions potentials are 
required at the point of the lesion to propagate the signal past the lesion (154).  Therefore 
carrying out low level contractions potentially pose a problem for MS patients as there is 
less central drive required to carry out a low level contraction; potentially this could 
result in an insufficient amount of electrical activity achieved at the point of the lesion to 
propagate the signal past the lesion.  However when high intensity contractions are 
required the central drive is heightened and the muscles are bombarded with electrical 
activity and hence more electrical activity will have reached the point of the lesion and 
hence maintained the signal along the neuron.  The amplitude results in the present study 
show that there is no difference between the groups over all the contractions, therefore it 
would appear that the patients’ low level contractions were not affected.  It may be that 
the 20% contraction was high enough to ensure the signal was propagated.  However it is 
intriguing when looking at the mean contraction intensity performed as patients carried 
out their 20% at an average of 28.24±8.32% for the dominant leg and 30.03±14.24% for 
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the non dominant leg; whereas controls carried out their 20% contraction much closer to 
their target intensity at 24.34±4.93% for the dominant leg and 23.82±3.79% for the non 
dominant leg.  It is possible the patients carried the contraction out at the lowest intensity 
that they were able to.  The central drive may have had to increase to ensure propagation 
along the neuron and past the lesions.  However, once the central drive was elevated the 
neural activity reaching the muscle would be more than required to carry out the intended 
contraction hence the contraction was carried out at a higher intensity.  The effect of 
neural propagation on spasticity of MS patients has been investigated.  Smith and 
McDonald (1999)(154) outlines the effect of temperature on conduction block.  Neural 
transmission of electrical impulse past the lesion is decreased as a result of a rise in body 
temperature.  Schwid et al (2003) (146) investigated the effects of a single acute dose of 
cooling therapy on MS patients.  They found that one high dose of cooling therapy 
produces significant improvements in neurological function. 
Taking the MFCV and the RMS results together indicates that MS patients, with a 
relatively mild disability status (EDSS; 2.5-6), do not exhibit any adaptations with the 
CNS or to neuromuscular characteristics within the periphery.  It may be that patients 
who exhibit a higher disability status do present with change in MFCV and RMS data; 
further research would need to be carried out to elucidate this.  The present study 
recruited patients with mild disability with impaired gait in order to ensure the 
contraction protocol could be carried out. 
5.3.3. Summary of Neuromuscular Characteristics 
In summary, as no difference in MFCV was identified between the groups this suggests 
that no intra muscular adaptations have taken place within the vastus lateralis of MS 
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patients.  Additionally, there was no difference in amplitude revealed between the two 
groups either, which indicates that no alterations in the neural activity received by the 
muscle exist in MS patients with relatively mild MS (EDSS 2.5-6).  Therefore this study 
can conclude that in the relatively early stages of MS no alteration within the CNS and no 
peripheral changes have taken place when comparing MS patients to an age and sex 
matched control group. 
5.4. Torque Production 
5.4.1. Absolute Torque 
Controls produced more absolute torque, whilst executing their MVC, than patients in the 
dominant and non dominant leg.  This is to be expected and is in line with previous 
research (35) with similar sample size that shows that patients MVC was lower than 
control participants.  In addition this study showed that patients were only able to 
generate 75±22% of their force generating capacity whereas controls were able to 
produce 94±6% of theirs.  The present study did not investigate the percentage of force 
generating capacity. 
There was no difference between the legs within the patient and the control group.  This 
is surprising as all patients presented with a reported affected leg and less affected leg yet 
no difference was identified between the legs within the group. 
5.4.2. Relative Torque 
There was no difference in torque production per gram of muscle between the two groups 
for either the dominant and the non-dominant leg nor was there any difference between 
the two legs within either group. 
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Therefore, although the control group produced more absolute torque than the patient 
group; when the torque was expressed relative to lean thigh mass the difference was 
revoked.  Torque per gram of muscle mass is indicative of muscle quality (46) and the 
results suggest that a gram of patients muscle is capable of producing the same torque as 
a gram of the controls muscle.  As the torque generating capacity of the muscle is the 
same this suggests that the intra muscular mechanisms that generate force must also be 
the same.  These include fibre type distribution (26), motor neuron activity (133), cross 
bridge cycling (60), Ca2+ ATPase activity (28) and energy metabolism (84).  These 
results support the neuromuscular results generated from the present study, as it is well 
documented that the neural activity received through the motor neuron dictates the 
phenotype of the motor unit (133).  The neuromuscular results from this study suggest the 
neural activity received by the patient and the control group were no different therefore it 
is not surprising that the force produced per gram of muscle mass also remained 
unchanged.  The maintenance of the neural activity received by the vastus lateralis in the 
patients group has resulted in the maintenance of intra muscular mechanisms and hence 
resulted in the maintenance of torque generating capacity. 
5.4.3. Absolute Lean Thigh Mass 
When absolute LTM was analysed no difference was identified when solely comparing 
the dominant or the non dominant leg between the two groups.  However; when both legs 
were considered together within each group a difference was identified between the two 
groups.  Therefore, the patient group overall exhibited reduced muscle mass in 
comparison to the control group.  However there was a difference in MVC between the 
groups for both the dominant and non dominant leg even though no difference in LTM 
was identified in either of the legs between the groups.  Therefore controls were able to 
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produce a greater absolute amount of force than the patient group whilst exhibiting a 
similar size muscle mass as the patient group.  This indicates that the patient group have a 
reduced muscle quality than the control group.  However because there was a difference 
in LTM between the group when considering both legs; this shows that the control group 
exhibit a greater thigh muscle mass than the patient group.  Therefore, there may not be a 
difference in muscle quality between the groups. 
In addition, there was no difference in absolute LTM between the two legs within each 
group.  This supports the previous finding that there was no significant difference in 
absolute force production between the dominant and non dominant leg within each group.  
As had been previously demonstrated muscle produces force relative to muscle cross 
sectional area.  Maughan et al (1983) (104) found a significant positive correlation 
between strength and cross sectional area for both males and female.  This demonstrated 
that as cross sectional area increased the maximum voluntary contraction was greater.  
Hence when no significant difference in MVC existed between the dominant and non 
dominant leg it follows that no difference existed in absolute LTM between the dominant 
and non dominant leg. 
It has been established that no difference in MVC or LTM exists between the dominant 
and non dominant leg within each group therefore effectively there is no difference 
between the two legs within each group.  This is surprising, especially within the patient 
group as most patients presented with a definite dominant leg.  These results may in part 
be down to the protocol carried out as the contraction took place on the Bio Dex Systems 
3 Isokinetic dynamometer.  When the participant was set up on the chair, the contraction 
angle and direction was dictated thereby removing any requirement for co-ordinated 
movement.  The contraction protocol also did not require alterations within the 
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contraction where the participant was required to react, again removing the need for co-
ordinated movement.  Therefore the protocol may have removed certain variables that 
effect MS patients’ movement in everyday living, thereby making the differences 
between the limbs appear less significant. 
Future research may be required to look more closely at the contribution that co-
ordination has on MS patients’ ability to carry out daily tasks.  It may be that their 
muscles have the function capacity to carry the task out but the reduced precision of 
movement results in failure of the task. 
5.4.4. Lean Thigh Mass Ratio 
Lean Thigh Mass Ratio1 (LTM Ratio) is used to express the lean mass of the thigh in 
comparison to the lean mass of the whole body.  When lean thigh mass ratio was 
analysed no difference was identified when only comparing the dominant or the non 
dominant leg between each group.  When both the dominant and the non-dominant leg 
were considered together within each group the difference was approaching significance 
(P=0.077).  This is similar to the results obtained when including both legs into the 
comparison of absolute lean thigh mass between the groups.  No difference had been 
identified when comparing only one leg but when both were considered a difference was 
revealed.  In the case of the LTM ratio the finding did not reach significance when adding 
both legs into the comparison however the result was approaching significance.  
Using LTM ratio is more robust than absolute LTM as the value is relative to the 
participants’ lean body mass; however it is interesting that the results for the LTM ratio 
tend to follow the same propensity as the absolute LTM. 
                                                 
1 Lean Thigh Mass (LTM) Ratio – LTM/ Lean Body Mass (LBM)*100 
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These results show that there is a tendency for the patients to exhibit muscle atrophy but 
only when both legs are considered in the comparison.  As there is no significant 
difference in LTM or force production between the dominant and non dominant leg 
within each group including both merely increases the sample size. 
This finding is interesting as when lean thigh mass increases this generally results from 
an increased use of the muscle through physical activity and this study shows that the 
control group was more active than the patient group.  As a result of an increase in 
physical activity the muscle will increase in size (105).  In addition to the increase in size 
the muscle should have exhibited neuromuscular adaptations to the increased neural 
activity received by the muscle.  This would manifest itself as an increased expression of 
type 1 muscle fibres within the muscle (165; 166).  Although a tendency for the size of 
the muscle to be greater in the control group was revealed in the present study no 
difference in neuromuscular characteristics were identified. 
5.4.5. Correlation of MFCV to LTM Ratio 
A negative correlation was revealed.  As LTM increases MFCV decreases.  This is what 
would be expected from a more trained muscle.  As you would expect the bigger muscle 
to have received more neural innervation and hence present with more type 1 muscle 
fibre and therefore present a lower MFCV. 
5.4.6. Summary of Torque Production 
Controls produced more absolute force than patients however when the force was 
converted to force per gram of muscle mass no significant difference was revealed.  
Therefore the quality of the muscle remained unchanged between the patient and the 
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control group.  Therefore; in MS patients with a disability status (EDSS) between 4 and 
6, there was no detectable deterioration in muscle quality. 
There was a tendency for patients to exhibit muscle atrophy as there was a difference 
between absolute LTM between the groups and the difference in LTM ratio between the 
groups was approaching significance.  This tendency for MS patients to exhibit muscle 
atrophy is supported by the finding that MS patients had a reduced level of physical 
activity. 
Therefore although there is a tendency for MS patients to have less functional muscle, the 
muscle that they do have exhibits no decline in muscle quality compared to the muscle of 
the age and sex matched control group. 
5.5. Body Composition 
Body composition in the present study was measured using Dual-energy X-ray 
Absorptiometry (DEXA) which is considered the reference method of body composition 
analysis (95).  The precision, using DEXA, of the total body fat mass, lean mass and bone 
mineral content, expressed as %CV, was 2.0, 1.11 and 1.09%, respectively (85).  
Therefore the body composition measurements obtained in the present study are highly 
accurate and reliable (153; 157). 
The radiation dose from a DEXA scan is very low and hence it is safe for sequential 
measurements to be made on volunteers (16; 19; 93) 
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5.5.1. Total Body Fat 
Results from the present study found a difference in total percentage body fat between the 
patient and the control group.  Controls had 30.6% (women 32.1, men 29.6%) body fat 
and patients had a higher level of body fat of 38.3% (women 40.5, men 35.8%).  
According to the National Institute of Health men with more than 25% percent body fat 
and women with more than 30% body fat are obese.  On average, both the men and 
women in each of the groups have a higher level of body fat than is recommended for 
optimal health (59). 
Percentage fat of the thigh, when considering both thighs, was different between the 
patient group and control group with patients exhibiting 44.13% and the control group 
exhibiting 34.27% fat.  In addition, there was a difference in percentage body fat between 
the two groups when comparing the dominant and non-dominant leg.  The percentage fat 
of the dominant thigh of the patient groups was 43.83% and the control group was 
34.28%.  The percentage fat of the non-dominant thigh for the patient group was 44.46% 
and the control group was 34.25%. 
It is interesting that percentage fat of the thigh was greater than percentage fat of the 
whole body.  This may explain why the MFCV values gathered in the present study are 
elevated in both groups.  High levels of subcutaneous fat are known to artificially elevate 
the MFCV value when using surface EMG techniques (110; 111).  The thigh appears to 
store a higher proportion of body fat than the body as a whole as patients had a whole 
percentage body fat of 38.27% and a combined thigh percentage fat of 44.13% and 
controls exhibited values of 30.16% and 34.27% respectively.  If this is the case it may be 
more accurate to use a muscle that is situated where body fat does not accumulate as 
readily, such as the tibialis anterior which is situated to the front to the tibia.  This muscle 
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is close to the skin and is less likely to be covered in high levels of body fat.  MFCV 
values may have been lower than the present study which utilised the vastus lateralis to 
gather EMG data.  Numerous studies (28; 80; 81; 83; 120; 121; 123; 148) which have 
investigated neuromuscular characteristics in health and disease have made use of the 
tibialis anterior muscle for data collection. 
5.5.2. Correlation of MFCV to Total Percentage Body Fat 
A positive correlation was identified between MFCV and percentage body fat; as body fat 
increased MFCV increased. This supports the contention that the surface EMG technique 
is affected by the subcutaneous layer of fat between the muscle fibre and the electrode.  It 
is possible that this technique may more appropriate in populations where the percentage 
body fat remains within a healthy range or in an athletic population, where the percentage 
body fat tends to be relatively low (160). 
5.5.3. Correlation of MFCV to Percentage Fat of the Thigh 
A consistent positive correlation was evident between MFCV and percentage fat of the 
thigh for both groups independently and in both groups together.  This indicates that 
MFCV increased with increasing levels of fat within the thigh.  This is likely to be as a 
consequence of methodological limitations as fat is known to artificially increase the 
conduction velocity value obtained (110).  However it is possible that the MFCV is in 
fact elevated in individuals with elevated levels of fat.  If high levels of fat are indicative 
of lower levels of physical activity then it can be assumed that the muscles of individuals 
with high levels of body fat receive less neural activity and therefore the resulting muscle 
will exhibit more fast muscle fibres and therefore have an elevated MFCV (165; 166). 
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5.5.4. Bone Mineral Density 
There was no difference in whole body or thigh BMD between the patient and the control 
groups.  Neither was there a difference between the dominant and non dominant leg 
within each group.  This is interesting as calcium homeostasis is closely linked to vitamin 
D metabolism.  Vitamin D deficiency causes bone mineral reabsorbtion (97) and hence 
results in a reduced bone mineral density; therefore had vitamin D deficiency existed 
within the MS population it would have been likely to have resulted in a reduced bone 
mineral density.  Results from the present study do not show any difference in Vitamin D 
concentration or BMD between the patient and the control group.  However research has 
suggested that vitamin D plays a role in the pathogenesis of MS (8) and that higher sun 
exposure between the ages of 6-15 years was associated with a lower risk of MS (8).  
Therefore it is possible that at some point in time a vitamin D deficiency may have 
triggered the disease in individuals who were genetically susceptible to MS but was not 
significant enough to cause major bone mineral resorption. 
Physical activity, especially weight bearing physical activity (48; 109), is known to 
increase BMD.  BMD has been shown to remodel in response to impact and hence the 
more physically active a person is the more likely they are to have a high BMD, assuming 
vitamin D and calcium homeostasis is maintained (109).  As the present study identified a 
significantly higher level of habitual activity in the control group, it would have been 
reasonable to expect the BMD to be higher too but this concept has not been supported by 
data from the present study.  Although a difference in activity levels was identified 
between the groups, the overall activity levels of both groups remain low.  Therefore, 
potentially the absolute difference in levels of physical activity was not great enough to 
manifest a difference in BMD. 
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5.6. Physical Activity 
5.6.1. Habitual Physical Activity Levels 
The results of the accelerometry data analysis show that patients are less habitually active 
than control participants as revealed by their mean and total counts per day.  This is in 
agreement with Ng and Kent-Braun (1997) (122) who also identified a significant 
difference in physical activity levels, using three dimensional accelerometers for 7 days, 
between MS patients and controls from groups of similar size to the present study. 
These physical activity findings support the absolute LTM and the LTM ratio results; the 
lower levels of physical activity apparent in the patient group may explain the tendency 
them to exhibit a lower LTM ratio than controls.  Although the result of the comparison 
between the LTM ratios between groups did not reach significance the fact that the 
absolute values, when considering both legs, did reach significance supports this 
contention. 
5.6.2. Effect of MS on Activity Levels 
It is not surprising that MS patients have reduced levels of habitual physical activity; 
patients often exhibit impaired gait hence have reduced mobility (102; 109).  It is also 
common for MS patients to experience fatigue (90; 119; 148) and therefore may rest or 
sleep throughout the day, resulting in a reduced level of daily physical activity.  In 
addition many MS patients are unable to work and as a consequence do not incorporate 
any occupational associated physical activity into their day.  Furthermore MS patients 
were previously advised by their physicians to avoid physical activity (11; 177) as the 
heat produced exacerbated their symptoms (11; 132; 175).  It is now more clearly 
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understood that this is a transient change (11; 175) and that the patients symptoms return 
to normal after the heat load. 
In addition, previous research suggests that MS patients have an increased energy cost of 
walking compared to control participants (125; 126), it is not surprising that the 
accelerometry data from the present study and from previous research (122) demonstrates 
patients as being less active.  MS patients have an elevated energy cost for a given work 
load so even light workloads will challenge their cardiovascular system and energy 
metabolism as oxygen requirement can be up to 4 times the requirement of control 
participants.  It is therefore reasonable that they tend not to raise their level of physical 
activity beyond relatively light work.   This may also explain why MS patients in the 
present study have not demonstrated a difference in MFCV, which is indicative of a high 
proportion of type II fibre within the muscle.  If patients are constantly requiring high 
levels of oxygen to carry out daily tasks they will be continually putting demands on their 
aerobic energy system.  As the aerobic energy system is being stressed it will adapt to be 
more efficient so that energy demands can be made; such as the effect of endurance 
training (79).  Therefore muscle fibres would adapt to become more aerobic in nature 
which is indicative of a slow twitch or a type I muscle fibre which transmits the action 
potential along the muscle fibre at a slower rate than the fast or type II muscle fibre (145).  
Contrary to this however previous research (82) has suggested that MS patients have a 
higher percentage of type 2 fibres than control participants which is consistent with bed 
rest (165; 166), spinal chord transaction (29) and long term paralysis (101).  Therefore it 
may be the case that MS patients do not raise their level of physical activity to the point 
where they stress their aerobic capacity.  At this point, they may experience discomfort 
and the sensation of fatigue and therefore cease physical activity.  Therefore the muscles 
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will never experience enough stress to adapt to become more aerobic.  Hence, MS 
patients  exhibit more type II muscle fibres (82). 
5.6.3. Benefits of Physical Activity 
Exercise programmes can increase muscle mass therefore muscle strength may be 
increased and walking efficiency improved (163), thereby reducing the individuals’ 
energy cost of walking, making daily living easier and allowing them to increase their 
habitual physical activity to levels where they would obtain health benefits. 
Physical activity should be encouraged as the patients can gain from the health benefits 
from exercise.  Numerous studies (65; 89; 119; 131; 159; 163; 176-178) have 
investigated the benefits of physical activity for MS patients.  Gutierrez et al 2005 (65); 
Taylor et al (2006) (163); White et al (2004) (178) and White et al (2006) (176) studied 
the effect of resistance training among MS patients.  Resistance training is good for MS 
patients as it is more targeted to specific muscle groups, it is slower and requires less co-
ordination than some aerobic type exercise.  It is also more controlled and reduces the 
risk of injury from falls during exercise.  Gutierrez et al (2005) (65) showed that after 2 
months of resistance training there was a significant increase (P<0.05) in stride time and 
stride length and isometric strength also improved in 2 out of the 4 muscle groups tested.  
Taylor et al (2006) (163) demonstrated that the MS patients who completed a progressive 
resistance programme twice a week for 10 weeks exhibited a significant increase in the 
leg press 1 repetition maximum and in fast walking speed and a highly significant 
increase in leg press endurance and arm press 1 repetition maximum.  This indicated that 
resistance training can be used to improve quality of life and maintain functional capacity 
in MS patients.  In addition patients will gain from the health benefits of physical activity 
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which will reduce the likelihood of them developing cardiovascular disease (88), type 2 
diabetes (147), the metabolic syndrome (128) and obesity (134).  If MS patients can 
avoid contracting lifestyle associated diseases the management of their MS becomes less 
complex (116). 
As well as the physical benefits, physical activity is know to improve psychological well 
being (87) and increase self image and mental well being (55) and therefore improving 
the patients’ quality of life. 
5.6.4. Correlation of MFCV to Total Physical Activity 
A strong positive correlation was identified between MFCV of the patients’ non 
dominant leg and patients’ total physical activity.  This indicates that MFCV increases as 
total physical activity is increased.  This is contrary to what is believed to happen.  
Studies (4; 10; 133) have shown that muscle fibres that are innervated with an electrical 
impulse adapt to become more like type 1 muscle fibres regardless of the nature of the 
innervation.  Whereas when innervation is removed, either from muscle preparations  or 
in spinal chord transection the muscle revert to type 2 muscle fibres and hence would 
exhibit a faster MFCV (29; 101; 133; 165).  Therefore in the present study a negative 
correlation was expected; where MFCV decreased as total physical activity increased.  It 
may be that the participants in this study where not physically active enough and those 
changes would only be seen when greater amounts of physical activity were taking place. 
The correlation of MFCV to total physical activity was not consistent throughout all the 
comparisons (see Table 4-20; in results section).  A negative correlation was obtained for 
two correlations and no correlation existed for the other three comparisons.  Therefore the 
highly significant correlation of the patients’ non dominant leg to total physical activity is 
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not representative of all the correlations made between MFCV and total physical activity.  
As the result is greatly different from the other correlations the significant result may be 
down to chance and consequently not indicative of a physiological relationship. 
5.6.5. Correlation of MFCV to Mean Physical Activity 
A similar finding was revealed from the correlation of MFCV to mean physical activity.  
The outcome of the correlation was inconsistent throughout the comparisons.  A highly 
significant correlation was identified within the patient non dominant leg however as the 
response throughout the comparisons are inconsistent it is unlikely that this highly 
significant finding is representative of a physiological relationship. 
5.7. Blood Sample Analysis 
5.7.1. Lipid Profile 
No significant difference existed between the patients and the control group for either 
cholesterol, triglycerides, HDL or LDL cholesterol.  This insinuates that the lifestyle 
variables which effect the blood lipid profile; such as diet (112; 130) and physical activity 
(51; 63; 94), are similar between the two groups. 
It is interesting that physical activity is reduced and percentage body fat increased within 
the patient population yet they exhibit a similar blood profile.  Physical activity is known 
to improve an individual’s blood lipid profile (51; 63; 94) therefore a less favourable 
blood lipid profile would be expected within the patient population. 
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5.7.2. Vitamin D Concentration 
A significant difference (P<0.05) in Vitamin D concentration between the patient and the 
control group was detected.  Vitamin D is one of the non-infectious agents that has been 
suggested to trigger MS in a genetically susceptible individual (8).  Research by Soilu-
Hanninen et al (2005) (155) demonstrated that MS patients exhibited a reduced level of 
Vitamin D than controls at the point of diagnosis. However Barnes et al (2007) revealed 
that no difference in Vitamin D levels existed between MS patients and controls (14).  
Vitamin D deficiency is widespread in the population in the absence of MS (69) therefore 
vitamin D deficiency is not the direct cause of MS although there is research to suggest 
an association with MS (7; 8). 
In addition the vitamin D results are consistent with the BMD findings; no difference in 
BMD was found between the groups and therefore the fact that no difference in vitamin 
D was found was consistent. 
The vitamin D analysis was carried out using only the values for the participants who had 
not been excluded from the trial due to insufficient EMG data.  However a blood sample 
had been taken from these participants and was analysed.  When statistical analysis was 
carried out on the vitamin D results from all the blood samples analysed the difference in 
vitamin D concentration between the patient and the control group was significant.  The 
control group exhibited a higher concentration of Vitamin D than the patient group.  This 
study could not identify the differences because a number of participants’ data was 
excluded from previous analyses and therefore had to be excluded from this analysis.  It 
is however important to look at this variable on its own because vitamin D is considered 
to be a risk factor for multiple sclerosis. 
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5.8. Methodological Implications 
5.8.1. Surface Electromyography and Alternative Techniques 
Surface electromyography (sEMG) is a non-invasive method used to measure the electric 
potential field evoked by active muscle fibres through intact skin (182).  The electrode 
placed on the skin detects depolarisation of the sarcolemma.  The validity of the 
measurement depends on a constant distance between the electrode and the sarcolemma; 
a thick subcutaneous fat layer can increase cross talk between motor units and introduce 
error into the data (156).  In the present study, on average, both the groups are classified 
as obese therefore the level of body fat may have introduced error to the data collected 
and may account for the high MFCV values obtained. 
The high level of fat in both groups may have also effected the orientation of the 
electrodes with respect to the muscle fibre direction.  Electrodes were situated midway 
between the innervation zone and the tendon of the vastus lateralis; they were placed on 
the surface of the skin along the pennation angle of the muscle fibre.  However when the 
contraction was carried out the layer of fat was displaced and hence resulted in the 
electrode being moved from its original position.  In addition to the effect of cross talk as 
a result of high levels of fat (156) the displacement of the electrode may have confounded 
the issue. 
In addition, the different intensity contraction may have resulted in the electrode being 
displaced to a different degree.  For instance the electrode may be displaced less during 
the 20% contraction than during the higher intensity contractions.  Therefore the EMG 
data from the 20% contraction may have been gathered from different muscle fibres than 
the higher intensity contractions.  As the signal may have been gathered from different 
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muscle fibres for the different contraction intensities the signal may have been generated 
from different fibre types, which in itself would result in different conduction velocities 
being recorded. 
In addition to the effect that high level subcutaneous fat has on the EMG recording fat 
distribution may also have an effect.  The DEXA results highlighted that the percentage 
fat of the thigh was in fact higher than the percentage fat of the whole body.  Therefore 
this shows that patients and controls store a disproportionately higher amount of fat 
around the thigh area.  An observation from the DEXA scan results is that more fat was 
stored higher up the thigh than towards the knee.  This means that there is a gradient in 
the distance between the sarcolemma and the skin surface for the whole length of the 
thigh.  It appears that there may have been higher levels of fat beneath the first electrode 
and the subsequently less fat under each of the other electrodes.  This has implication on 
EMG recordings as even slight differences in the volume of fat beneath each electrode 
may have a significant effect.  However, whole body and percentage fat of the thigh was 
high within both groups so the effect of high levels of body fat were similar between the 
groups. 
Intramuscular EMG techniques are also used to measure MFCV along muscle fibres;  
needle electrodes are inserted into the muscle at a set distance apart whereby measuring 
the impulse along the muscle fibre more directly (5; 182).  This technique removes 
variables that affect the EMG such as level of subcutaneous fat between the muscle and 
skin.  This may be a more viable technique when measuring electrical activity of muscle 
fibres in patient and sedentary populations where high levels of body fat may be 
prevalent. 
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5.8.2. Accelerometry 
The GT1M accurately and concisely measures time varying acceleration ranging in 
magnitude from 0.05 to 2.0 G’s (according to manufacturers technical details) in order to 
measure level of habitual physical activity.  However the accelerometer detects 
movement from some activities better than others.  For example the monitor is more 
likely to register activity counts from activity that required movement as the monitor 
gathers information through gravitational acceleration.  Therefore, during activities such 
as walking, participants’ hips are moving therefore the monitor will detect the movement.  
However, during activities such a cycling where the legs are working but the hips are not 
moving, the physical activity count for that activity may be underestimated.  Also, the 
device fails to identify the alterations in gradient, therefore it could underestimate 
physical activity if they were climbing a set of stairs or going up a hill.  In addition, the 
activity monitor cannot be worn in the water therefore if someone’s main mode of 
physical activity was swimming accelerometry would greatly underestimate their habitual 
level of physical activity.  Especially in a patient population who may rely on swimming, 
as it is a gentle form of exercise and specifically in MS as swimming can be carried out 
without an increase in body temperature (11) which is known to exacerbate their 
symptoms (86; 146; 154). 
However, although these limitations reduces the likelihood of collecting accurate data, 
the same limitations exist for all participants and therefore the data collected for all 
participants are comparable.  In addition, accelerometry is an objective method that is 
more accutate and reliable than subjective methods, such as recall questionnaires, which 
have several limitations (140). 
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5.8.3. Mode of Analysis of Accelerometry Data 
Debate exists in the literature on the best way to analyse accelerometry data.  It is 
common practice in accelerometry research to remove zeros from individual data sets if 
the zero has recurred continuously for 20 minutes or more (140).  Various methods exist, 
however it is becoming more apparent that one method may not be correct for all 
populations.  For instance, in a patient population it is not unusual for them to sit down 
for 20 minutes or sleep for a while during the day.  If a string of zeros of up to 20 minutes 
was removed then the average counts per day will over estimate their level of habitual 
activity; however the total counts per day will remain unaffected.  The intention of the 
acclererometry is to get an accurate value of actual physical activity and leaving the zeros 
in will do this more accurately than removing them.  In the present study the method of 
removing a string of zeros of 60 minutes or more was used.  This reduced the likelihood 
of removing zeros when the participant had in fact been inactive, thereby reflecting their 
mean level of physical activity more accurately. 
Furthermore the same method of analysis may not be appropriate for both patients and 
controls.  However it is possible that accelerometry data should be analysed differently to 
suit the population, or kept the same in order to make a valid comparison.  In the present 
study the same method of removing zeros was used for both the patient and the control 
group. 
Accelerometry data can also be used to indicate how long the participant spent in 
different intensities of activity such as; sedentary, light, moderate and vigorous activity.  
This method was not used in the present study primarily because physical activity is a 
secondary outcome and not the main finding.  In addition the cut points which designated 
the different activity level were developed on a young healthy population and these cut 
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points may not be indicative of these activity levels in older and diseased populations 
(57).  It has been shown that MS patients have an energy cost of walking up to four times 
greater than controls (125; 126).  Therefore for any given value generated by the 
accelerometer the MS patients’ energy cost will be much higher than if that value was 
generated from a control participant.  The cut point would therefore not accurately 
describe the length of time that patients spent in each activity level; hence the decision 
was made to only use average and total counts for analysis of accelerometry data in the 
present study. 
5.8.4. Sample Size 
The original power calculation for this study indicated that 18 participants were required 
in each group to detect significant differences in MFCV.  It was decided to aim to recruit 
20 participants for each group to allow for drop out or spurious data.  Every effort was 
made to recruit 20 participants into each group, however this proved not to be possible.  
Initially, 18 participants were recruited into the control, which in fact, met the power 
calculations minimum value.  Only 16 patients were recruited, however this included 
almost all of the MS patients within the local MS societies who fitted the disability 
criteria and who were willing to participate.  As a result of falling short of the power 
calculations values we may have missed some differences that do exist but were unable to 
identify.  The sample size recruited was sufficient to detect a difference in MFCV 
between the groups in the dominant leg however had we obtained the larger sample size 
we may have been able to identify differences between the non-dominant legs as this was 
approaching significance. 
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However, in order to increase the patients sample size the area of recruitment would have 
to be greatly increased.  This study, was advertised with MS societies within the central 
belt, however research suggests that there is a clustering of MS in Tayside in Scotland 
(44) and therefore if the recruitment area was increased to include Tayside the sample 
size may be adequate to identify any differences in MFCV. 
5.9. Conclusion 
MS patients exhibited faster MFCV with a similar number of motor units recruited than 
healthy ages and sex matched controls.  An increased quantity of subcutaneous fat 
artificially elevates MFCV (110) and MS patients in this study had exhibited higher 
percentage fat than the controls.  Therefore, when accounting for this confounding 
variable we then showed that there was in fact no difference in MFCV between the 
groups.  However the patients MFCV responded differently to the increased contraction 
intensity than the controls which suggests altered neuromuscular processing within the 
patient group. 
The MS group had reduced physical activity levels which caused a slight disuse atrophy 
of the lower limbs which did not compromise muscle quality.  Therefore, similar quality 
of the muscle has resulted in unaltered neuromuscular recruitment in MS patients. 
Overall, the results indicate that there was no difference in neuromuscular characteristics 
of MS patients compared to age and sex matched controls, even in the presence of altered 
body composition and physical activity levels. 
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Application no #161 Muscle Fibre Conduction Velocity of Multiple Sclerosis Patients 
during Isometric Contractions of the Knee Extensor 
 
Thank you for your response from my letter of 26th June; I am happy that you have 
satisfied the conditions required; therefore you are now eligible to proceed with the 
study. 
 
We wish you the best of luck with your study. 
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Dr Angus Hunter 
Chair of Sport Studies Ethics Committee 
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0*********** 
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Are you: 
Between 18 and 65 years of age? 
 
Interested in assisting with health research! 
 
Wish to gain feedback on your current state of health! 
 
• Leg Strength 
• Cholesterol Level 
• Accurate measure of body composition (fat and muscle) 
• Physical activity level analysis 
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Are you:  An MS Patient 
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Interested in assisting with research into multiple sclerosis 
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Wish to gain feedback on your current state of health 
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• Cholesterol Level 
• Accurate measure of body composition (Fat and muscle) 
• Physical activity level analysis 
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You are invited to take part in a study being carried out by the University of Stirling.  In order to participate 
in the study you should fit the following description: 
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• Mobile or mobile with an aid 
• 18-65 years of age 
• Free from cardiac complaints 
• Free from MS 
 
The study is comparing muscle function between MS patients and control participants.  The information 
sheet explains what you will be asked to do if you agree to take part.  Before you decide it is important for 
you to understand what is involved.  Please take time to read the following information carefully and 
discuss it with others if you wish. 
 
If there is anything that you are not clear about or if you would like more information on the study please 
contact Sasha Scott on:  0********** or s.m.scott@stir.ac.uk 
 
Thank you for taking the time to consider participating in this study. 
 
Yours sincerely 
 
 
 
 
 
Sasha Scott 
Postgraduate Research Student 
Department of Sport Studies 
University of Stirling 
Dr Adrienne Hughes 
Supervisor 
adrienne.hughes@stir.ac.uk 
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Dear [Patient] 
 
PATIENT INVITATION FOR STUDY OF MUSCLE FUNCTION IN MS PATIENTS 
 
You are invited to take part in a study being carried out by the University of Stirling.  In order to participate 
in the study you should fit the following description: 
 
• MS patient 
• Male or Female 
• Mobile or mobile with an aid 
• 18-65 years of age 
• Free from cardiac complaints 
 
The study is comparing muscle function between MS patients and control participants.  The information 
sheet explains what you will be asked to do if you agree to take part.  Before you decide it is important for 
you to understand what is involved.  Please take time to read the following information carefully and 
discuss it with others if you wish. 
 
If there is anything that you are not clear about or if you would like more information on the study please 
contact Sasha Scott on:  0*********** or s.m.scott@stir.ac.uk 
 
Thank you for taking the time to consider participating in this study. 
 
Yours sincerely 
 
 
 
 
 
Sasha Scott 
Postgraduate Research Student 
Department of Sport Studies 
University of Stirling 
Dr Adrienne Hughes 
Supervisor 
adrienne.hughes@stir.ac.uk 
 
Sasha Scott 
Dept. of Sport Studies 
University of Stirling 
Stirling 
FK9 4LA 
 
0********** 
s.m.scott@stir.ac.uk 
DATE: [DATE] 
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Participant and Patient Information Sheet 
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PARTICIPANT INFORMATION SHEET 
 
MUSCLE FUNCTION IN MS PATIENTS 
 
 
You are invited to take part in a research study that is being carried out in fulfilment of a 
Master of Philosophy (MPhil) degree at the University of Stirling.  Before you decide 
whether or not to take part it is important for you to understand what is involved. 
Please read this information sheet carefully. 
1. What is the purpose of the study? 
The purpose of this study is to determine if there is a difference in muscle fibre 
conduction velocity (MFCV)* in Multiple Sclerosis (MS) patients compared with age 
and sex matched control participants. 
*Muscle Fibre Conduction Velocity is the speed at which an electrical impulse travels 
along a muscle fibre to trigger a muscular contraction. 
2. Why have I been chosen? 
You have been chosen as you are the same gender and are similar in age to one of our 
MS patients.  The study aims to match each MS patient to an age and sex matched 
control participant in order for us to make a comparison. 
We aim to recruit 20 MS patients and 20 age and sex matched controls. 
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3. Do I have to take part? 
No.  It is up to you to decide whether or not to take part.  Participation is voluntary.  
Payment will not be given for participating in the study; however participants will be 
reimbursed for travel expenses up to the value of £10. 
If you decide to take part you are free to withdraw from the study at any time and 
without giving a reason. 
4. What will happen to me if I take part? 
• Measurement of your physical activity habits using Acceleromtery 
• Diet log for 24 hours prior to testing 
• 1 visit to the laboratory 
• 1 Dual-energy X-ray Absorptiometry (DXA) scan to measure body composition 
Accelerometry 
We will ask you to wear an accelerometer, which is a little box that measures your 
level of physical activity by detecting movement.  The accelerometer is attached to a 
belt which is worn around your waist and situated on your right hip.  The 
accelerometer should be worn during all waking hours for 7 days.  The accelerometer 
is small and can be worn under clothing without being noticed. 
Laboratory Visit 
The main part of the study involves one visit to the physiology laboratory at the 
University of Stirling.  You will be asked to write down all the food and drink you 
consume for the 24 prior to your laboratory visit. 
On arrival at the laboratory you will have your blood pressure measured and a blood 
sample* taken.  Weight and height will be measured; we will also take a skin fold 
measurement of your thigh muscle. 
* As we are taking a blood sample, you will be asked to fast for 12 prior to your 
laboratory visit.  The blood sample will be taken first; you will then be offered tea or 
coffee, a roll and some fruit. 
We will place electrodes on the skin surface over your thigh muscle to record the 
electrical impulse along the muscle.  In order for the electrodes to pick up a clear 
signal we must first prepare the skin by shaving the area, then wiping it clean with an 
alcohol swab. 
*Electrical impulses are naturally occurring in the muscle.  You will not feel any 
difference between contracting your leg with or without the electrode on your skin.  
This is a completely non-invasive procedure. 
The strength of your thigh muscle will be measured on a Bio-Dex isokinetic 
dynamometer (pictured on page 1).  You will be strapped into the seat and your leg 
attached to a lever (same as the picture).  You will be asked to push your leg away as 
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if you are trying to straighten it however the lever will not move causing a static 
contraction.  While you are doing the static contraction the Bio-Dex measures the 
force that your thigh muscle is producing. 
We will ask you to perform four sub-maximal contractions to familiarise yourself 
with the procedure.  You will then perform two maximal contractions (i.e. push your 
leg away as hard as you can).  You will then be asked to complete sub maximal 
contractions at 20, 40, 60 and 80% of your maximum.  You will then be asked to 
complete sub maximal contractions at 20, 40, 60 and 80% of your maximum.  
Carrying out 3 contractions at each level; we will ask you to carry out each 
contraction for 7 seconds.  You will be given 14 seconds rest in between each 
contraction. 
Dual-energy X-ray Absorptiometry (DXA) 
The DXA scan will be carried out at Yorkhill Children’s Hospital in Glasgow.  
Transport will be provided if it is required.  The DXA scan is a non-invasive 
procedure and is used to obtain an accurate measurement of fat mass, muscle mass 
and bone density.  The DXA scanner gives a very small dose of radiation; much less 
than the amount of background radiation you would be exposed to from being outside 
for one day.  Therefore this scan poses no health risk.  You are required to lie still for 
about 10 minutes until the scan is complete. 
5. Do I have to change anything if I take part? 
You are not required to change any aspect of your lifestyle as a result of taking part in 
this study.  Continue to take any medication that you have been prescribed and 
continue to follow your usual routine. We do however ask that you refrain from any 
form of strenuous exercise on the day before laboratory testing. 
6. What is the procedure that is being utilised? 
We are using a procedure called Surface Electromyography (sEMG) to obtain the 
main findings for this study.  sEMG is a non invasive technique, where electrodes are 
placed onto prepared skin.  The electrodes pick up electrical activity in the muscle 
below the surface of the skin. 
7. What are the possible problems of taking part? 
When asked to perform a maximal contraction, changes occur within the body to 
meet the demands of the effort.  Heart rate, blood pressure and breathing rate can all 
increase.  These are normal responses to a maximal effort.  You will be given time to 
recover before you are asked to carry out the remaining contractions. 
 
The DXA scan involves a small amount of radiation.  We are all exposed to a small 
amount of radiation when we are outside.  You get the same amount of radiation from 
the scan as you would from being outside for a few hours one day.  Therefore this 
procedure poses no health risk. 
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One blood sample will be taken; you may experience a slight scratch as the needle 
punctures the skin.  If you feel that the discomfort is too much the procedure will be 
stopped.  The rest of the study can still continue as planned. 
8. What are the possible benefits of taking part? 
There are no intended clinical benefits to you from taking part in this study. 
You may be related or have close association with someone who suffers from MS.  
Participating in this study will add to the body of knowledge and may improve the 
treatment for MS patients in the future. 
You may be interested in taking part in the trial to find out information on your 
habitual level of physical activity (accelerometry), analysis of cholesterol levels and 
obtain accurate measurements of body composition (DXA Scan).  These 
measurements give you a good indication of your current state of health. 
9. What if something goes wrong?  
If something goes wrong Stirling University carries Public Liability cover in respect 
of its legal liability for loss or damage to third party property and death or personal 
injury to any person not being an employee. 
10. Will my taking part in this study be kept confidential? 
The information collected about you in this study will be anonymised, i.e. linked to a 
special code that is stored separately on a password-protected computer file.  Your 
identity will only be known to members of the research team.  All information 
obtained in the study will be stored securely in the Dept of Sport Studies at the 
University of Stirling, and retained for a period of 6 after which it will be destroyed.'  
With your permission, we will inform your GP (family doctor) of your participation 
in this study. 
11. What will happen to the results of the research study? 
The result of this study will be used to complete a thesis for a master’s degree.  In 
addition the results may be published in a medical journal. 
You will not be identified in any report/publication. 
In the event that any unusual observations occur, such as high blood pressure or 
raised cholesterol, we will, with your permission write to your GP and inform him/her 
of this observation. 
12. What happens to my blood sample? 
Your blood sample will be tested separately for Vitamin D content and Cholesterol 
levels. 
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The blood samples obtained in the study will be stored securely in the Department of 
Sport Studies Laboratory and retained for a period of 5 years.  With your permission 
we would like to use the sample in future research concerning multiple sclerosis. 
13. Who is organising and funding the research? 
The University of Stirling, Department of Sport Studies is organising and funding this 
research project. 
14. Who has reviewed the study? 
This study has been approved by the University of Stirling, Department of Sport 
Studies Ethics Committee. 
15. Contact for Further Information 
Principal Researcher 
 
Sasha Scott 
Postgraduate Research Student 
Department of Sport Studies 
Cottrell Building 
University of Stirling 
Stirling 
FK9 4LA 
 
s.m.scott@stir.ac.uk 
0*********** 
 
Supervisor 
 
Dr Adrienne Hughes 
Department of Sport Studies 
Room 3-A51 
Cottrell Building 
University of Stirling 
Stirling 
FK9 4LA 
 
adrienne.hughes@stir.ac.uk 
0*********** 
Thank you for reading this Information Sheet and considering taking part in this study. 
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PATIENT INFORMATION SHEET 
 
MUSCLE FUNCTION IN MS PATIENTS 
 
 
You are invited to take part in a research study that is being carried out in fulfilment of a 
Master of Philosophy (MPhil) degree at the University of Stirling.  Before you decide 
whether or not to take part it is important for you to understand what is involved. 
Please read this information sheet carefully. 
16. What is the purpose of the study? 
The purpose of this study is to determine if there is a difference in muscle fibre 
conduction velocity (MFCV)* in Multiple Sclerosis (MS) patients compared with age 
and sex matched control participants. 
*Muscle Fibre Conduction Velocity is the speed at which an electrical impulse travels 
along a muscle fibre to trigger a muscular contraction. 
17. Why have I been chosen? 
You have been chosen as you have been diagnosed with MS and you are mobile or 
mobile with an aid.  
This study aims to recruit 20 MS patients who are mobile or mobile with an aid and 
are aged between 18 and 65 years of age. 
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18. Do I have to take part? 
No.  It is up to you to decide whether or not to take part.  Participation is voluntary.  
Payment will not be given for participating in the study; however participants will be 
reimbursed for travel expenses up to the value of £10. 
If you decide to take part you are free to withdraw from the study at any time and 
without giving a reason.  A decision to withdraw or a decision not to take part, will 
not affect the standard of care you receive. 
19. What will happen to me if I take part? 
• Measurement of your physical activity habits using Accelerometry 
• Diet log for 24 hours prior to testing 
• 1 visit to the laboratory 
• 1 Dual-energy X-ray Absorptiometry (DXA) scan to measure body composition 
Accelerometry 
We will ask you to wear an accelerometer, which is a little box that measures your 
level of physical activity by detecting movement.  The accelerometer situated on your 
right hip and attached to a belt which is worn around your waist.  The accelerometer 
should be worn during all waking hours for 7 days (with the exception of showering 
or swimming).  The accelerometer is small and can be worn under clothing without 
being noticed. 
Laboratory Visit 
The main part of the study involves one visit to the physiology laboratory at the 
University of Stirling.  You will be asked to write down all the food and drink you 
consume for the 24 prior to your laboratory visit. 
On arrival at the laboratory you will have your blood pressure measured and a blood 
sample* taken.  Weight and height will be measured; we will also take a skin fold 
measurement of your thigh muscle. 
* As we are taking a blood sample, you will be asked to fast for 12 prior to your 
laboratory visit.  The blood sample will be taken first; you will then be offered tea or 
coffee, a roll and some fruit. 
We will place electrodes on the skin surface over your thigh muscle to record the 
electrical impulse along the muscle.  In order for the electrodes to pick up a clear 
signal we must first prepare the skin by shaving the area, then wiping it clean with an 
alcohol swab. 
*Electrical impulses are naturally occurring in the muscle.  You will not feel any 
difference between moving your leg with or without the electrode on your skin.  This 
is a completely non-invasive procedure. 
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The strength of your thigh muscle will be measured on a Bio-Dex isokinetic 
dynamometer (pictured on page 1). You will be strapped into the seat and your leg 
attached to a lever (same as the picture). You will be asked to push your leg away as 
if you are trying to straighten it however the lever will not move causing a static 
contraction.  While you are doing the static contraction the Bio-Dex measures the 
force that your thigh muscle is producing. 
We will ask you to perform four sub-maximal contractions to familiarise yourself 
with the procedure.  You will then perform two maximal contractions (i.e. push your 
leg away as hard as you can).  You will then be asked to complete sub maximal 
contractions at 20, 40, 60 and 80% of your maximum.  Carrying out 3 contractions at 
each level; we will ask you to carry out each contraction for 7 seconds.  You will be 
given 14 seconds rest in between each contraction. 
Dual-energy X-ray Absorptiometry (DXA) 
The DXA scan will be carried out at Yorkhill Children’s Hospital in Glasgow.  
Transport will be provided if it is required.  The DXA scan is a non-invasive 
procedure and is used to obtain an accurate measurement of fat mass, muscle mass 
and bone density.  The DXA scanner gives a very small dose of radiation; much less 
than the amount of background radiation you would be exposed to from being outside 
for one day.  Therefore this scan poses no health risk.  You are required to lie still for 
about 10 minutes until the scan is complete. 
20. Do I have to change anything if I take part? 
You are not required to change any aspect of your lifestyle as a result of taking part in 
this study.  Continue to take any medication that you have been prescribed and 
continue to follow your usual routine. We do however ask that you refrain from any 
form of strenuous exercise on the day before laboratory testing. 
21. What is the procedure that is being utilised? 
We are using a procedure called Surface Electromyography (sEMG) to obtain the 
main findings for this study.  sEMG is a non invasive technique, where electrodes are 
placed onto prepared skin.  The electrodes pick up electrical activity in the muscle 
below the surface of the skin.  
22. Is there any danger or discomfort associated with this protocol? 
When asked to perform a maximal contraction, changes occur within the body to 
meet the demands of the effort.  Heart rate, blood pressure and breathing rate can all 
increase.  These are normal responses to a maximal effort.  You will be given time to 
recover before you are asked to carry out the remaining contractions.    
 
The DXA scan involves a small amount of radiation.  We are all exposed to a small 
amount of radiation when we are outside.  You get the same amount of radiation from 
the scan as you would from being outside for a few hours one day.  Therefore this 
procedure poses no health risk. 
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One blood sample will be taken; you may experience a slight scratch as the needle 
punctures the skin.  If you feel that the discomfort is too much the procedure will be 
stopped.  The rest of the study can still continue as planned. 
23. What are the possible benefits of taking part? 
There are no intended clinical benefits to you from taking part in this study. 
As an MS patient you may wish to participate in a study which may contribute to the 
body of knowledge and therefore may benefit MS patients’ treatment in the future.   
You may be interested in taking part in the trial to find out information on your 
habitual level of physical activity (accelerometry), analysis of cholesterol levels and 
obtain accurate measurements of body composition (DXA Scan).  These 
measurements give you a good indication of your current state of health. 
24. What if something goes wrong?  
If something goes wrong Stirling University carries Public Liability cover in respect 
of its legal liability for loss or damage to third party property and death or personal 
injury to any person not being an employee.  
25. Will my taking part in this study be kept confidential? 
The information collected about you in this study will be anonymised, i.e. linked to a 
special code that is stored separately on a password-protected computer file.  Your 
identity will only be known to members of the research team.  All information 
obtained in the study will be stored securely in the Department of Sport Studies at the 
University of Stirling, and retained for a period of 6 years after which it will be 
destroyed. 
With your permission, we will inform your GP (family doctor) of your participation 
in this study. 
26. What will happen to the results of the research study? 
The result of this study will be used to complete a thesis for a master’s degree.  In 
addition the results may be published in a medical journal. 
You will not be identified in any report/publication. 
In the event that any unusual observations occur, such as high blood pressure or 
raised cholesterol, we will, with your permission write to your GP and inform them of 
this observation. 
27. What happens to my blood sample? 
Your blood sample will be tested separately for Vitamin D content and Cholesterol 
levels. 
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The blood samples obtained in the study will be stored securely in the Department of 
Sport Studies Laboratory and retained for a period of 5 years.  With your permission 
we would like to use the sample in future research concerning multiple sclerosis. 
28. Who is organising and funding the research? 
The University of Stirling, Department of Sport Studies is organising and funding this 
research project. 
29. Who has reviewed the study? 
This study has been approved by the University of Stirling, Department of Sport 
Studies Ethics Committee. 
30. Contact for Further Information 
Principal Researcher 
 
Sasha Scott 
Postgraduate Research Student 
Department of Sport Studies 
Cottrell Building 
University of Stirling 
Stirling 
FK9 4LA 
 
s.m.scott@stir.ac.uk 
0*********** 
 
Supervisor 
 
Dr Adrienne Hughes 
Department of Sport Studies 
Room 3-A51 
Cottrell Building 
University of Stirling 
Stirling 
FK9 4LA 
 
adrienne.hughes@stir.ac.uk 
0*********** 
Thank you for reading this Information Sheet and considering taking part in this study. 
 
  
Appendix E 
 
Pre-Participation Health Screen Questionnaire 
 
Consent From 
 
Data Capture Sheet 
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Pre-Participation Health Screen Questionnaire 
 
The purpose of the pre-participation health screen is: 
To optimise safety during exercise testing 
To identify medical risk factors which may contra-indicate exercise. 
 
 
 
Name  Date of Birth  
 
Address  
 
  
Phone No.  Mobile  
 
Gender  Work No  
Doctor’s Name  Phone No.  
Surgery 
Address  
 
 
Physical Activity Index 
   Tick which one applies to you 
Activity Level Times per week Risk level  
Inactive 0 occasional Very High  
Semi-active 1 High  
Active 2-3 Moderate  
Very active 4 or more Low  
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SECTION A MEDICAL HISTORY 
Have you ever been told that you have had or have any of the following conditions? 
If yes, please mark with an X in the appropriate box: 
CARDIAC (Heart Related Diseases)   
ο Heart Attack ο High blood pressure 
ο Coronary thrombosis (blood clot) ο Rheumatic fever 
ο Narrowing of arteries ο Angina / Chest Pain 
ο High cholesterol ο Congenital Heart Disease  
ο Further / comments   
 
PULMONARY (Lung Diseases)   
ο Asthma ο Exercise-induced asthma 
ο Chronic Bronchitis ο Emphysema 
ο T.B.   
ο Other / comments   
 
OTHER   
ο Type I Diabetes ο Type II Diabetes  
ο Anaemia (ion deficiency)   
ο Kidney disease   
ο Rheumatoid Arthritis   
 
ORTHOPAEDIC SURGERY (Musculoskeletal) 
            
ο Neck ο Hip 
ο Back ο Knee 
ο Shoulder ο Ankle 
ο Arm ο Foot  
ο Other / comments   
 
INJURY 
Have you suffered any of the following injuries? If so, how long ago? 
ο Neck vertebrae ο Back vertebrae 
ο Rotator cuff ο Impingement Syndrome 
(shoulder) 
ο Tennis elbow ο Runner’s knee 
ο Ileal Tibial Band Syndrome ο Lower leg  
ο Achillies Tendonitis ο Plantar Fascitis  
ο Other / comments   
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MEDICATION 
Do you use medication at present for any of the following? (If yes, please state the 
drug) 
ο Heart rhythm ο Blood pressure 
ο Blood clotting. ο Blood circulation 
ο Asthma ο Bronchitis 
ο Emphysema ο Flu 
ο Diabetes ο Thyoid dysfunction 
ο Cholesterol ο Anaemia 
ο Kidney ο Liver 
ο Arthritis ο Muscle injury 
ο Other / comments 
 
SECTION B  CARDIOVASCULAR DISEASE RISK INDEX 
Please read the following questions carefully and answer each accurately. Mark your 
choice with an X. 
 
History of heart attack or bypass surgery / angioplasty 
0 ο None 5 ο 1 – 2 years ago 
2 ο Over 5 years ago 8 ο < 1 year ago 
4 ο 3 – 5 years ago    
 
Age/Gender Index 
 
0 ο Male / female under 30 years of age 
1 ο 30 – 40 years of age 
2 ο Female 40 - 50 years of age 
3 ο Male 40 – 50 years of age 
3 ο Female 50 – 60 years of age 
4 ο Male 50 – 60 years of age 
4 ο Male / female 60+ years of age 
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Smoking status 
0 ο None 
1 ο Pipe 
2 ο 1 – 10 cigarettes daily 
3 ο 11 – 20 cigarettes daily  
4 ο 21 – 30 cigarettes daily 
5 ο 31 – 40 cigarettes daily 
6 ο 41 – 60 cigarettes daily 
8 ο + 60 cigarettes daily 
State how long you have smoked for: 
Years______________months____________ 
 
 
Diabetes 
0 ο None 
1 ο Type 2 (non-insulin dependent) 
2 ο Type 1 (insulin dependent) 
 
Occupational Activity 
level 
  
1 ο Intense physical labour 
2 ο Moderate (walk often etc.) 
3 ο Sedentary 
 
Work Stress Tension   
0 ο No stress, very relaxed 
1 ο Moderate work stress and relaxed personality 
2 ο High work stress but cope well 
3 ο Very high work stress and tense personality 
4 ο Very high work stress, highly strung 
personality 
 
Physical Activity Status (for a minimum of 30 minutes a session) 
1 ο Exercise 4 or more times per week 
2 ο Exercise 2 – 3 times per week 
3 ο Recreational sport once a week 
4 ο Recreational sport occasionally or complete lack of exercise 
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SECTION C  EXERCISE PARTICIPATION 
 
Do you participate in any of the activities more than twice weekly? 
(Please tick all relevant activities) 
ο Jogging more than 5 km ο Aerobic classes 45 min 
ο Cycling more than 45 min. ο Tennis 90 min 
ο Swimming more than 600 m ο Squash 45 min. 
ο Gym (Combined strength / 
aerobic) 
ο Team sport (outdoor) – rugby hockey, 
soccer 
ο Gym (weights only) ο Team sport (indoor) – basketball, 
netball, etc 
ο Gym (aerobic only) ο Canoeing / Rowing 45 min 
    
 
SECTION D 
I have read, understood and completed this questionnaire to the best of my knowledge. 
 
Signature:  Date  
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Patient Identification Number for this trial: 
 
CONSENT FORM 
Title of Project:  MUSCLE FUNCTION IN MS PATIENTS 
Name of Researcher: SASHA SCOTT 
                                                                                                                    Please initial box 
1. I confirm that I have read and understood the information sheet dated 24 
Sept 2007 (Version 2) for the above study.  I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily. 
 
2. I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving any reason, without any medical 
care or legal rights being affected 
 
3. I agree to my GP being informed of my participation in this study.  
4. I agree to my GP being informed of the results of any of the tests that 
might have a bearing on my health or future care. 
 
5. I agree to my left over blood sample being retained and used in future 
multiple sclerosis medical research 
 
6. I agree to take part in the above study.  
     
Name of Participant  Date  Signature 
     
Name of person taking consent  Date  Signature 
 
When complete, 1 for participant; 1 for researcher site file. 
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DATA CAPTURE SHEET 
 
Participant Study Code  
Date  
 
Gender Male  Female  
Dominant Leg Left  Right  
Questionnaire Completed  Incomplete  
Blood Sample Lipids  Vitamin D  
 
Height (cm)  cm 
 
Weight (Kg)  Kg 
Weight as fat (Kg)  Kg 
% fat  % 
BMI  
 
Resting Heart Rate (bpm)  
Blood Pressure (mmHg) Sys:  Dia:  
 
Left Leg (nM) 100% MVC  
 20%:  40%:  
 60%:  80%:  
 
Right Leg (nM) 100% MVC  
 20%:  40%:  
 60%:  80%:  
 
Accelerometry  
Given Out - Date  
Date set to data collect  
 
